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INT.ROWCTION

Aminoglycoside antibiotics are irn}:x:>rtant in the treabnent of
serious to life-threatening bacterial infections.

'Ihese antibiotics

are used extensively as evidenced. by the approximately
given annually in the United states alone.

3

million doses

HDW'ever, the use of

aminog1ycoside antibiotics is often hanjpered by associated toxicities.
One of the most common toxicities encountered with these antibiotics
affects the kidneys (nephrotoxicity).

Although aminoglycoside

nephrotoxicity is usually reversible and mild in severity, it can
result in

some

degree of morbidity and lengthen hospital stay.

If gone

undetected, however, aminoglycoside nephrotoxicity can progress to
irreversible renal (kidney) failure and cond.emn a patient to dialysis
(Cooper

& Bennett, 1987).

Considerable research has been directed at dete:rmining the
interrelationships between aminoglycoside antibiotics and
nephrotoxicity.

Gentamicin and tobrarnycin specifically, have drawn a

great deal of attention, particularly after early animal data ind.icated
that tobrarnycin might be asscx:::iated with less nephrotoxicity than
gentamicin (Kahl.meter & Dahlager, 1982).

Comparative clinical trials

have produced. discrepant results as to whether gentamicin is associated
with nephrotoxicity more often than tobrarnycin (Burkle, 1986).

Results

from the same investigators have even been discrepant (Smith, Lipsey,
Iaskin, Hellmann, Mellitis, IDngstreth, & Liebnan, 1980; Moore, Smith,
Lipsey, Mellits, & Liebnan, 1984).
Several atterrpts have been made to discern from the errpirical
research whether there is a difference in the incidence of
1

2

nephrotoxicity between gentamicin and tobramycin (Burkle 1986; Cone,
1982; Darr & Elenbaas, 1981; Hubler, 1984; Kahlmeter & Il9hlager, 1982;
Meyer, 1986; Smith

&

Ll.etJnan, 1982).

However, the conclusions

presented in these reviews have been as discrepant as the ind.ependent
empirical (i.e. primary) f :i.n:::lings.
'Ihe question of gentamicin and tobramycin

~tive

nephrotoxicity is important because if tobramycin is associated with
less nephrotoxicity than gentamicin, morbidity related to gentamicin
nephrotoxicity could be reduced by preferentially using tobramycin.
HDW'ever, since gentamicin is significantly less expensive to use than
tobramycin, if there is no difference in nephrotoxicity between them,
then by using gentamicin preferentially, financial resources that would
have been consumeCl by tobramycin use could be reallocated for other
purposes.
Given that which is reported. above, it is apparent that the
previously published reviews of the empirical research comparing
gentamicin and tobramycin nephrotoxicity yielded inconsistent results.
It is important to note that meta-analytical techniques were never
systenatically applied to the existing database.

In the study

discussed belCM, meta-analytical techniques were used in an attempt to
provide a better understanding of the

~tive

nephrotoxicity of

gentamicin and tobramycin than achieved by the previously published
narrative reviews.
Meta-analysis represents a group of methodologies that are used
to systenatically and quantitatively combine results of ind.ividual
empirical research efforts to derive conclusions that may not be

3

achievable otherwise.

Meta-analyses are distinguished from narrative

reviews by their quantitative nature.

'Ihe proce:lure has been

criticized because of the heterogeneity that may exist among the
results and methcxls that are combined.

Al though there are methcxls to

control for the possible heterogeneity across studies, meta-analytic
synthesis of research findings will never take the place of a
well-done, definitive study.

Meta-analytic procedures are perhaps best

reserved for situations where definitive studies are not logistically
possible, or as an exploratory activity to determine whether such a
study should be undertaken (Mintz, 1983).
Considering the importance of the comparative nephrotoxicity of
gentamicin and tobramycin, and the discrepancy that presently exists in
both the primary and secondary literature, a meta-analysis might
provide a better overall picture.

'Ihus, a meta-analysis of the

comparative nephrotoxicity of gentamicin and tobramycin was undertaken
to primarily dete:nnine in a quantitative fashion whether such a
difference exists, and if so, to "What de;:Jree.
A parametric meta-analytic procedure (standardized mean
differences) was used to detect and quantify any differences in the
comparative nephrotoxicity of gentamicin and tobramycin.

HO'Wever, not

all comparative studies of gentamicin and tobramycin nephrotoxicity
provided enough infonnation to apply the parametric procedures.
Therefore, a mcxtified vote-counting method was used to analyze those
studies that could not be analyzed by the parametric procedures.

Thus,

a secondary purpose of this research project was to compare these two
meta-analytical techniques.

REVIEW OF REIATED LITERA'IURE

COmparative Nephrotoxicity of Gentamicin and Tobramycin
Aminoglycoside antibiotics.

Aminog'lycoside antibiotics are a

group of antibiotics that share similar chemical structures and
properties.

Many of the aminoglycoside antibiotics are commonly used

in the trea'bnent of serious to life-threatening bacterial infections.
In

same cases they represent the most effective or the only effective

antibiotics available (Pancoast, 1988).
The first aminoglycoside antibiotic made available for general
clinical use in the United States was streptomycin in 1944.

'Ihe next

aminoglycoside antibiotic to be approved for use was kanamycin in
1957, followed by gentamicin in 1969, tobramycin in 1975, a:mikacin in
1976, and netilmicin in 1983.

'Ihe aminoglycosides antibiotics have

seen extensive use with approximately three million doses administered
annually in the United states (Pancoast, 1988).
'Ihe use of aminoglycoside antibiotics, hOVJever, is hampered by
their asscx;iated toxicity.

The most common toxicities encountered with

the use of aminoglycoside antibiotics are ototoxicity and
nephrotoxicity.

ototoxicity refers to toxicity affecting auditory

function and nephrotoxicity refers to toxicity affecting kidney
function (Pancoast, 1988). Nephrotoxicity, spec:ifically, has been the
subject of significant research and debate.

Part of the research and

debate has concerned the relative nephrotoxicity of one aminoglycoside
to another, particularly gentamicin and tobramycin (Kahlmeter
Dahlager, 1984).
Aminoglycoside nephrotoxicity.
4

Nephrotoxicity

O<'.DlrS
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&
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approximately 10-20% of aminc.qlycoside courses of therapy.
Aminoglycoside antibiotics are taken up into renal tubular cells;
however, the cellular mechanism of toxicity is not known.

The

clinical presentation of aminoglycoside nephrotoxicity is usually an
asy:rrptoroatic accumulation in the serum of measurable metabolic prcxlucts
that are nonnally excreted by the kidneys (Cooper & Bennett, 1987).
For exanple, creatinine, which is a metabolic prcxluct of muscle, is
prcxluc.ed at a relatively constant rate and is excreted by the kidney.
Therefore, as renal function decreases (as occurs secondary to
nephrotoxicity), excretion of creatinine decreases correspondingly and
accumulates in the serum (Ravel, 1978) • Other m:mifestations of
nephrotoxicity can include detection of various enzymes or proteins in
the urine (Schentag, 1983).
Aminoglycoside nephrotoxicity typically occurs within seven to 10
days after initiation of therapy and is usually reversible with
discontinuation.

Aminoglycoside nephrotoxicity that goes undetected

can progress to severe degrees ultima.tely requiring dialysis.

Risk

factors that have 1:::leen associated with aminoglycoside nephrotoxicity
include age, aminoglycoside dose, duration of therapy, recent
aminoglycoside exposure, preexisting renal dysfunction, concurrent
administration of other nephrotoxins, p::>tassitnn depletion, and
intravascular vol1.m1e depletion (Cooper

&

Bennett, 1987).

The degree

to which specific aminoglycoside antibiotics contribute to the risk of
nephrotoxicity has 1:::leen the subject of considerable debate.
Gentamicin and tobramycin nephrotoxicity.

Farly anima.l data

suggesting that tobramycin might be less nephrotoxic than gentamicin

6

resulted. in subsequent clinical trials (COoper

&

Bennett, 1987).

'Ihe

in'portance of detenn.ining the comparative nephrotoxicity of gentamicin
arrl

tobrarr(Ycin encompasses both clinical arrl economic considerations.

From a purely clinical perspective, even the slightest suggestion that

tobrarr(Ycin is less nephrotoxic than gentamicin would lead many
clinicians to use tobrarr(Ycin to :minimize any urrlue morbidity related to
gentamicin.

However, economic considerations cloud the decision

because tobrarr(Ycin is several times more expensive to use than
gentamicin.

If there is no difference in the degree of nephrotoxicity

associated. with gentamicin arrl tobrarr(Ycin, then use of gentamicin
would pennit reallocation of the financial resources necessai:y for
tobrarr(Ycin to other uses.
Published comparative studies of gentamicin arrl tobrarr(Ycin
nephrotoxicity have produced equivocal results; some studies showing
tobrarr(Ycin to be less nephrotoxic than gentamicin "While others showed
no difference.

Many authors (Burkle, 1986; Cone, 1982; Darr &

Elenbaas, 1981; Hubler, 1984; Kahl.meter & Dahlager, 1982; Meyer, 1986;
Smith & Lietman, 1982) have attenpted. to evaluate the errpiric research.
'Ihese evaluations were either narrative reports with subjective
conclusions or analyses of pooled data; none of "Which used recognized
meta-analytical techniques.

Like the errpiric research they reviewed,

these evaluations produced equivocal conclusions.
Burkle (1986), Darr arrl Elenbaas (1981), Hubler (1984), Meyer
(1986), arrl Smith arrl Lietman (1982) each reported the results of
published canparisons of gentam.icin arrl tobrarr(Ycin nephrotoxicity,
cited methodological arrl clinical considerations, arrl rendered
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subjective conclusions.

Burkle evaluated 12 c:arrparative trials and.

concluded "that these 12 clinical trials failed to demonstrate any
difference in nephrotoxicity between these agents" (p. 516).

Hubler

reached a similar conclusion after evaluating 15 c:arrparative trials,
stating " the results of controlled studies in humans suggest that
there are no marked clinical differences in the nephrotoxicity of
gentamicin and. tobraroycin" (p. 3), as did Meyer in stating that "it is
still too risky to conclude definitely that one agent is significantly
less nephrotoxic that another and. that controversy still abounds" (p.
126).

In contrast, after evaluating approximately the same published

database, Darr and. Elenbaas concluded "that tobraroycin has less

nephrotoxic potential than does gentamicin" (p. 325) and. Smith and.
Liet::man concluded "tobraroycin causes nephrotoxicity less frequently
than does gentamicin" (p. 507) •

Cone (1982) and. Kahl.meter and Dahlager (1982) attempted
quantitative analyses of the c:arrparative studies of gentamicin and.
tobraroycin nephrotoxicity.

Cone pcoled the results as reported in

selected c:arrparative studies and. conducted pairwise corrpa.risons
(chi-square) to test for statistical significance.

'!he difference

between gentamicin and. tobraroycin nephrotoxicity did not reach
statistical significance.

Similarly, Kahl.meter and. Dahlager pcoled the

results as reported from selected comparative studies of gentamicin and
tobraroycin nephrotoxicity.

However, the pcoled proportions of

gentamicin and. tobraroycin nephrotoxicity (14% versus 12.9%) were not
subjected to hypothesis testing.
In sununa.ry,

despite several attempts to determine the comparative

8

nephrotoxicity of gentamicin and tabramycin by summarizing published
results, the question of comparable nephrotoxicity still rema.ins.
Applying meta-analytical techniques to this database could provide more
meaningful infonnation than the previously published reviews to help

solve this important question.
Meta-Analysis
Definition and characterization.

Definitions and

characterizations of "meta-analysis" va:r:y because meta-analysis as a
research methodology is relatively new and is still evolving (Mintz,
1983).

The beginning of meta-analysis as a distinct methodological

entity has been traced to Glass in 1976 (Mintz, 1983; Thacker, 1988);
however, research techniques associated with meta-analysis had been
employed prior to 1976 (Glass, Mc::Gaw, & Smith, 1981; Ieviton & Cook,
1981; Sacks, Berrier, Rei'bnan, Ancona-Berk, & Chalmers, 1987).
Glass (1976) originally defined meta-analysis as "the statistical
analysis of a large collection of results from individual studies for
the purpose of integrating the findings" (p. 3).

later, Glass, McGaw

and Smith (1981} defined meta-analysis as "the analysis of analyses

(i.e., the statistical analysis of the findings of many individual
analyses) 11 (p. 12).

other definitions of meta-analysis are similar.

Mintz (1983) defined meta-analysis as "a quantitative methodology for
integrating empirical research literature" (p. 71).

Meta-analysis is

defined by Thacker (1988) as "an attempt to irrprove traditional methods
of narrative review by systematically aggregating infonnation and
quantifying its lirpact" (p. 1658), and by L'Abbe, Detsky and O'Rourke
(1987) as "the process of combining study results that can be used to

9

draw conclusions about therapeutic effectiveness or plan new studies"
(p. 224).

'Ihus, most authors define meta-analysis as a method or as

methods to combine empirical (i.e., primacy) research for the purpose
of deriving or inproving generalizations.
Glass et al. (1981) have characterized meta-analysis as a method
by which quantitative analyses of empirical research are conducted by
adopting an "attitude" of data analysis (i.e., using measurement and
statistical analysis techniques).

It can be considered as a methcrl of

summarizing an accumulated knowledge and highlighting :i.nportant
aspects ('Ihacker, 1988).

Meta-analysis also addresses research

questions that rema.in unresolved ~ (a) empirical data are in
I

disagreement as to the direction or ma.gnitude of an effect, (b) sample
sizes used in the primacy research were too small to detect an effect,
or (c) the large trials necessary are not logistically feasible (L'Abbe
et al. 1987).

In

contrast to traditional narrative reviews in which

typically there are no rules by vmich the reviewer assesses the
relevant primacy research, meta-analysis requires systematic approaches
to aggregating empirical infonration and quantifying its effect to

produce more ·ruid generalizations (Fiske, 1983; 'Ihacker, 1988) •
Corrrrnon to the definitions and characterizations of meta-analysis
is the "quantitative" nature of the methods used to review empirical
research, particularly relative to the traditional "narrative"

methods.

'Ihe

degree to which meta-analysis "quantifies" empiric

research is variable and often limited.

Mintz (1983) conceptualized

the review process on a continuum based on the degree to which
quantitative methods are used as follCMS:

10
As the review prcx::ess progresses from the descriptive narrative
summary to the abstract heights of the multiple regression
analysis, a series of steps is taken by the reviewer. Each step
involves increased quantification and abstraction. (p. 71)
Thus, on one end of the continmnn are narrative reviews in which
quantitative integration of empiric research is absent and
subjectivity reigns.

The next step aloncJ the continmnn firds

narrative reviews that include tabular or graphical presentations of
the ernpiric research substrate that invite mmnnarization but do not
integrate individual findings or synthesize new info:nna.tion.

The next

step crosses into meta-analytic methcxiology 'Wherein codincJ schemes are
userl to facilitate descriptive mmnnaries of the ernpiric research.

The

complexity of methcrlologies continue to increase al011CJ the continmnn to
ultimately "the introduction ot:)pferential statistical hypothesis
1

testincJ" (p. 72) •
Although quantitative aspects are ernphasizerl 'When definincJ or
characterizincJ meta-analysis, there are necessary qualitative aspects
as well.

For example, qualitative judgments in a particular

meta-analysis could include the population of studies considererl
relevant, the scope of the ernpiric research substrate to analyze, and
the methcxiological approaches to ernploy (Ieviton
11

&

Cook, 1981).

Thus,

just as quantitative research presupposes qualitative judgments, so

qualitative research is inpossible without quantitative estimates" (p.
232).
Nomenclature.

''Meta-analysis" was the tenn used by Glass in 1976

to denote methcxis by which ernpirical research is integraterl to
emphasize or synthesize info:nna.tion from large bcx:lies of data.
However, like the methcxiologies of meta-analysis, the nomenclature

11
remains unsettled (Light, 1987).
Meta-analysis is a tenn used frequently in both the social (Glass
et al., 1981) and medical sciences (L'Abl:::le et al., 1987).

"Research

integration" and "research synthesis" are also tenns that have been
used with same re;JU]_arity, "While other authors prefer the tenn

"ovezview'' (Light, 1987) •

Presently none of these tenns refer to

specific types of methods to integrate empiric research, and are
therefore used interchangeably.

Tenns used

exclusively in the

physical sciences for meta-analysis are "critical review" and "critical
evaluation" (Hedges, 1987).
Need for meta-analvs is.
specifies two carrq;xments.

One

model for scientific research

'Ihe first COIIpOnent is empiric research from

'Which primary data are derived.

'Ihe second COIIpOnent is integration

and interpretation of the results of empiric research.

Meta-analysis

sezves as one methodological approach to this second component of
scientific research of integration and interpretation (Fiske, 1983).
The need for the second COIIpOnent of scientific research in
clinical medicine relates to the variability in results that occur
despite the use of oontrolled methods in empiric research such as the
randomized controlled trial.

Horwitz (1987) enunciated the problem as

follavs:
Clinical medicine is awash in controversy. At every level of
clinical practice today, from prevention of the chronic diseases of
aging such as cancer, to the treatment of acute disorders such as
myocardial infarction, the evaluation and application of medical
therapies is assailed by disagreement and uncertainty. In
contemplating the health hazards of such diverse entities as
tampons (and the alleged risk of toxic shock syndrome) or aspirin
(and the alleged risk of Reye's Syndrome), the methodologic
strategies and details of the research are frequently challenged
and criticized, creating controversy and dissention in the

12

scientific literature and. the public press. (p. 91)
Reasons for the state of the medical literature as Horowitz
describes it have been attributed to specific methodolcx3"ical errors or
problems inherent in the research paradigm itself.

Specific

rnethodolog-ical errors can include experimental designs that result in
bias or statistical shortcomings such as insufficient sanple sizes or
eniployment of inappropriate analytical techniques.

Inherent problems

in research paradigms often relate not to compliance with the
componentry of the paradigm, but with the variable interpretations of
their use and. applications (Horowitz, 1983).
'!he narrative review has been the predominant method by which
enipiric research has been assessed in the clinical medicine literature.
Prior to the acceptance and. application of controlled. methods of
experimentation in clinical research, the fo:rm of the published. medical
literature was primarily reports of random observations.

'!bus, there

was little primary research that could be integrated; and. therefore,

the narrative review served. to describe the state of the art (fye,
1987).
As controlled. methods of experimentation in clinical research
became widely applied., mostly in the fo:rm of randomized controlled

trials, narrative reviews became less reliable as a means to summarize
the enipiric data.

'!be burgeoning size of the medical literature, as a

result of specialization and. the pressures to publish, also add to the
inadequacy of narrative reviews to accurately summarize primary data
(fye, 1987) • From Janua:ry 1, 1984 to August 1, 1986 alone,
approximately 6,000 randomized. clinical trials were indexed. inMEDLilIB
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(Chalmers, Levin, Sacks, Reibn.an, Berrier, & Nagalingam, 1987b).

'Ihus,

as the conplexity and amount of the e.npiric research continue to
increase, the chance for misinterpretation and bias will increase
accordingly (Einarson, McGhan, Boobn.an, & Sabers, 1985; Strube &
Harbnann, 1983; '!hacker, 1987).

It could be argued that what is needed are not methods to
integrate e.npirical research, but e.npiric research that is conducted to
definitely answer the research questions at hand.

Hovvever, logistical

considerations often preclude design of the definitive e.npiric research
effort, particularly those that will likely only demonstrate small to
mcx:ierate magnitudes in effect that necessarily require large sample
populations difficult to assemble (Collins, Gray, Godwin, & Peto,
1987).

'!he inherent nature of the ra:rrlomized clinical trial paradigm

also often produces divergent results from seemingly identical methods
(Horovvitz, 1987).

'Ihus, as Fiske (1983) noted:

In the long-range perspective, no one study makes much difference
(except the rare one that falls more in the context of discovery by
uncovering something previously undemonstrated). Granted that the
single study may stimulate or irritate in a healthy fashion, only
the distillations from the entire body of research in an area have
lasting effects. (p. 65)
'!he meta-analysis of Yusef, Collins, Peto, FLU:berg, Stampfer,
Goldhaber, and Hennekens (1985) assessing the effect of intravenous
fibrinolytic therapy for acute myocardial infarction is an illustrative
example.

Prior to their meta-analysis, the place of fibrinolytic

therapy for acute myocardial infarction had been uncertain despite the
publication of over 20 clinical trials over a period of 25 years.

Of

the 24 ra:rrlomized clinical trials of intravenous f ibrinolytic agents
for acute myocardial infarction included in the meta-analysis, only
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five suggeste::i any benefit from this therapeutic intervention in tenn.s
of mortality.

However, Yusef et al. derived an overall reduction of

mortality of approx.irnately 22% using the odds ratio of mortality in the
fibrinolytic groups to mortality in the control groups.

'Ihe overall

odds ratio was derived by weighting irxtivid:ual study odds ratios

inversely by variance.

It thus appeared that intravenous fibrinolytic

therapy for acute myocardial infarction could affect a mortality
benefit, but that the magnitude of effect might be rocxierate thereby
necessitating large sample sizes for reliable detection.

As a result

of this meta-analysis, two large, multi-center, rand.ornized,
placebo-controlled trials were und.ertaken to confinn these findings.
P>Oth the Grupp:> Italiano Per lo Studio Della Streptochinasi
Nell'Infarto Miocardico (GISSI) (1985) trial and. the ISIS-2 (Second
International Study of Infarct survival) Collaborative Group (1988)
trial that enrolled 11,806 and. 17,189 patients, respectively,
demonstrated a reduction in mortality associated with the use of
intravenous fibrinolytic therapy (streptokinase) for acute myocardial
infarction of a similar magnitude as the Yusef et al. meta-analysis.
In surmnacy, it is rare that an irxtivid:ual empirical research
effort can provide definitive and reproducible results.

'Iherefore,

meta-analysis can be considered as "an equally illlportant activity of
interpreting and integrating the results of the empirical studies that
have been done" (Fiske, 1983, p. 65).
Meta-analysis in clinical medicine.

Meta-analysis as a technique

to integrate empiric research in clinical medicine has lagged behind
the need.

As evidence, in reviewing the first ten issues published in
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1982 of the New England Journal of Medicine, Journal of the American
Medical Association, British Medical Journal, and Lancet, Halvorsen
(cited in DerSimonian & laird, 1986) found only one of 589 articles
that applied fonnal statistical methods to combine results.

Mulrow-

(1987) evaluated 50 review articles published between June, 1985 and
June, 1986 in the Annals of Internal Medicine, Archives of Internal
Medicine, Journal of the American Medical Association, or New England
Journal of Medicine.

Although some degree of qualitative synthesis

(e.g., describing differences in sa.Irple populations, intervention
approaches, outcome measures) was attenpted in 43 of the 50 reviews,
qualitative synthesis of the empiric research covered was attempted in
only three.

In an assessment of review articles published in Clinical

Phannacy, Drug Intelligence and Clinical Phannacy, Drugs, and
Phannacotherapy, Hendrickson and Amerson (1986) did not even include an
analysis of the methcxlolcqies used in the reviews.

Thus, it appears

that not only is the primary literature lagging in the application of
meta-analytical techniques, but some of the assessments of the review
literature even fail to look for them.
In 1987, sacks et al. published an evaluation of meta-analyses in
clinical medicine to date.

In

their search for meta-analyses they

discovered that although the first was published as early as 1955, only
13 others were published during the subsequent 25 years.

HDW'ever, they

discovered an apparent new appreciation for meta-analysis beg"inning in
1980 by finding 69 published between 1980 and 1987.
Since meta-analysis has been only sparingly used in clinical
medicine, there have been few assessments of them.

Sacks et al. (1987)
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evaluated 86 meta-analyses published in the clinical medicine
literature meeting the inclusion requirement that at least one of the
studies used in an individual meta-analysis be a rarrlomized controlled
trial.

F.ach meta-analysis was reviewed for study design,

cornbinability, control and measurement of p::>tential bias, statistical
analysis, sensitivity analysis, and application of results.
'!he most notable aspect concerning the study design of the
meta-analyses evaluated by Sacks et al. (1987) was the paucity of
details provided.

In only seven percent of the meta-analyses was the

protocol described and in only 35% was the literature search strategy
detailed.

Although the studies included were rep::>rted in nearly all

meta-analyses, a list of the studies excluded was rarely provided.
Treatment assigrnnent (i.e. , rarrlamization) within included studies

was

described for most meta-analyses but few (22%) provided details
concerning the ranges in patient, disease, and treatment
characteristics across studies.
Sacks et al. (1987) found that less than half (45%) of the 86
meta-analyses evaluated described any differences that existed among
studies included.

Less common among the evaluated meta-analyses (20%)

were statistical methodologies used to detennine homogeneity among
included studies.
overall, Sacks et al. (1987) found adequate control and
measurement of p::>tential bias infrequently among the 86 evaluated
meta-analyses.

None rep::>rted details to ensure that methods and

results were considered separately by the individual meta-analysts.
In addition, in none were blinded data-extraction and measurement of
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interobsel::ver agreement employed in conjunction.
Adequate statistical methods for meta-analysis for the purpose of
their evaluation was defined by Sacks et al. (1987) as "any reco:;Jlrized
method of pooling except the sinple addition of successes across all
trials to give an overall average" (p. 452).

'Ihose that reported only

sinple addition of successes were considered "partial".

Adequate

statistical methods were used in 66% of the 86 evaluated meta-analyses.
Consideration of 'fype I and 'fype II errors were acknowledged in 45% of
the meta-analyses.

Confidence intervals were reported in 43% and

subgroup analyses were conducted in 63%.

Among the 86 meta-analyses evaluated by Sacks et al. (1987), few
sensitivity analyses were applied.

Assessing the quality or making

adjustments for differences in quality among studies in individual
meta-analyses were discovered in only 19%.

The issue of quality of

individual studies was acknowledged in less than half (47%).

Only 16%

of the meta-analyses assessed the effects of different asst.nnptions,
tests and criteria.

While about 17 (20%) of the meta-analyses

acknowledged the problem of publication bias, in only two were
adjustments attempted.
Sacks et al. (1987) found that the inplications of the
meta-analyses as the authors saw them were included in 77%.

However,

economic considerations were only fully explored in one and addressed
to a lesser degree in 17 (20%).
overall, of the six major cat.eg"ories of meta-analyses assessed by
Sacks et al. (1987), only 24 (28%) of the 86 addressed at least one
issue in all six categories.

Thirty-one (36%) addressed at least one
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issue in five of the categories, 25 (29%) addressed four categories,
five (6%) addressed three categories, and. one (1%) addressed two
categories.

'Iberefore, although the use of meta-analysis is increasing

in clinical medicine, methodologies and. quality vary considerably and.
improvement is generally warrante:l.
Using the same meta-analyses as Sacks et al. (1987), Chalmers et
al. (1987b) assessed the degree by which meta-analyses of smaller
controlled trials agreed with larger co-operative studies.

A

meta-analysis involving 12 studies of intravenous beta-adrenergic
receptor antagonists for acute myocardial infarction in a total of
4,408 patients produced similar results (i.e, confidence intervals of
effect) as two separate large co-operative trials, one of which
included 5, 778 patients and. the other 16,027.

A meta-analysis of

intravenous streptokinase for acute myocardial infarction involving 11
randomized controlled trials and. a total of 5,268 patients resulte:l in
a similar magnitude of effect as a large co-operative study involving
11,712 patients; however, the confidence interval was narrower for the
large co-operative study.
contrasting results of a

Of interest in this comparison were the
particular~

analysis wherein the

meta-analysis indicate:l a favorable effect from the treatment and. the
large co-operative study indicate:l a favorable effect from the
control.

'!be other comparison of Chalmers et al. was that between a

meta-analysis of the effect of phenobarbital for prevention of
intracranial hemor:rhage in newborn infants involving seven studies and.
a total of 413 patients with a co-operative study involving 280
patients.

'!be results differed; however, the confidence intervals
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overlapped.
Again using the same group of meta-analyses as Sacks et al.
(1987), 01almers, Berrier, Sacks, Ievin, Reitman, and Nalgalingham
(1987a) evaluated statistical and clinical agreement of meta-analyses
concerning the same errpiric research.

To the original 86 published.

meta-analyses, five unpublished. meta-analyses were added..

Among the 91

meta-analyses, 46 represented replicate analyses of 20 different
treatments (i.e., 20 cohorts).

The levels of statistical agreement

were (a) experimental therapy significantly better (:g < .05), (b) trend
in favor of experimental therapy (:g > .05), (c) no apparent statistical
effect, (d) trend favoring control group(!?> .05), and (e) control
group significantly better(!?< .05).

The levels of clinical

agreement were gauged. on the meta-analysis authors' enthusiasm and were
(a) strongly favoring experimental therapy, (b) mod.erately favoring
experimental therapy, (c) no difference of clinical interest, (d)
moderately favoring control, and (e) strongly favoring control.

The 20

cohorts were divided. into two groups; one group in which all
meta-analyses agreed within each cohort and another in which at least
one meta-analysis within each cohort was in disagreement.

This was

done for both statistical and clinical scales.
Among the 20 cohorts there was statistical agreement in 10 and
disagreement in 10.

Among the 10 cohorts in which there was

statistical agreement, treatment was favored in eight.

In the 10

cohorts in which statistical disagreement existed., the disagreement was
often between adjacent levels (e.g., l? < .05 and l? > .05); therefore,
agreement in direction of effect often occurred despite statistical
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disagreement.
cohorts.

Clinical agreement was recorded for six of the 20

Of the six cohorts with clinical agreement, treatment was

favored in five.

As

occurred with statistical disagreement, the

rna.gnitude of clinical disagreement was typically adjacent levels.

All

six cohorts in clinical agreement were also in statistical agreement.
No differences in agreement/disagreement status were observed within
selected cohorts in which inclusion and exclusion criteria differed
(e.g., meta-analyses including all published and unpublished research
versus meta-analyses including only randomized controlled trials).
Therefore, this preliminary evaluation of meta-analysis in clinical
medicine indicates that there may be differences in the results between
meta-analyses covering the same empirical research; however, the
difference is usually in rna.gnitude and not direction.

In addition,

differences are more conuron to authors' interpretations of the results
than statistical results.

As

concluded by the authors:

Although this paper does not settle the question of whether metaanalyses of clinical trials as now perfonned have sufficient
scientific rigor to reveal reproducible facts, the process must
continue in the future; hopefully, disagreements will disappear as
meta-analyses methodology becomes more rigorous. The extent of
agreement is encouraging, and, taken with the apparent lack of
disagreement between results of meta-analyses of small trials
compared with large, co-operative studies, suggest that one should
not discourage, on the basis of their anticipated size alone, well
designed and conducted small trials. (p. 740)
The current need for meta-analysis rna.y soon become an
expectation.

The Ad Hoc: Working Group for Critical Appraisal of the

Medical Literature (Mulrow, Thacker, & Pugh, 1988) recently published
guidelines that call for meta-analytical techniques to be applied to
reviews of medical literature.

Einarson et al. (1985) have recormnended

"that meta-analysis be used for drug reviews published in the pharmacy
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literature" (p. 1962).
Meta-analysis methcrlology.

If the analogy of I..ouis, Fineberg,

and Mosteller (1985) that "meta-analysis is to primary a research study

as a primary research study is to its study subjects" (p. 1) is
accepted, then conceptual approaches to empiric research can be applied
to meta-analysis.

'Ihus, the typical steps required in conducting a

meta-analysis include (a) defining a research question, (b} searching
and retrieving relevant literature (i.e., subjects}, (c) defining

inclusion and exclusion criteria, and screening the relevant literature
retrieved (i.e, screening subjects}, (d} describing and analyzing the
data, and (e} reporting and interpreting results (I..ouis et al., 1985;
Thacker, 1988).

The foundation upon which any meta-analysis is built is the
clearly defined research question.

Concerning research questions as

they relate to clinical medicine, Yusuf (1987) advised that, "the
question should always be framed in the context of the supposed
mechanisms of drug action and the known epidemiology of that particular
disease" (p. 281).
research

question.

All subsequent steps are necessarily related to the
In addition, covariates of interest also detennine

subsequent methcrlological direction.

'Iherefore, no other steps towa:rd

conducting a meta-analysis should be taken until the research question
is clearly settled (Light, 1987; Thacker, 1988).
'!he validity and generalizability of a completed meta-analysis is
related, in part, to the degree in which the data relevant to the
research question is covered.

'Iherefore, systematic processes to

retrieve all relevant data are necessacy.

'Ihese data retrieval
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processes include (a) electronic searches of appropriate databases
(e.g., MEDLmE and Embase for clinical medicine literature), (b) manual
searches through the reference sections of previously retrieved
literature, and (c) contacting colleagues or other possible sources
(e.g., govennne:ntal agencies, manufacturers) for unpublished
infonnation ('!hacker, 1988).
None of the methcxis used for meta-analysis directly address the
choice of inclusion and exclusion criteria to be employed.

The

inclusion and exclusion criteria are dependent on the research question
and researcher predispositions concerning what can and cannot be

legitimately pooled

(~ts,

1987).

At present there are no accepted

rules concerning the basic parameters that must be present for a
particular study to be included in a meta-analysis.
of continued debate among meta-analysts.

'Ihis is a subject

The study parameters

considered by meta-analysts acceptable for inclusion span a continuum
from randomized controlled trials without confounding variables to all
"relevant" studies (independent of fo:rm) including those considered
flawed.

Independent of the parameters by which the meta-analyst

employs in selecting empiric data, it must be consistent and taken .into
consideration when making .inferences from the results (Ll.ght, 1987) .
There are many analytical methcxis used in meta-analyses.
general, there are two basic analytical approaches used.

In

One is

combfuing' significance levels and the other is combining magnitudes of
effect (Strube & Harbna.nn, 1983).

The fo:rm of the outcome data of

interest and the amount of infonnation available dictate, in part,
which analytical approach is employed.
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Analyses that combine significance tests are generally used when
little infonnation is provided in the errg;>iric research substrate.

The

basic premise of combining significance levels is "that it allows the
reviewer to detennine whether a set of results could have arisen by
chance" (st:rube & Hartmann, 1983, p. 15).

There are several procedures

used to combine statistical significance levels, some of which have
been

described by Hedges

&

Olk.in (1985, chap. 3) • These procedures are

necessarily nonparametric and can be difficult to interpret.

They only

detennine whether a difference exists and provide no infonnation in
tenns of ma.gnitude of effect (Demets, 1987).
A related approach to combining statistical significance levels
knCMn as ''vote-counting" is based on the proportion of studies within a

meta-analysis that reach statistical significance.

A relationship

between ind.ependent and dependent variables is considered significant
if a "plurality" of studies reach statistical significance.

Hedges and

Olkin (1985, chap. 4) have criticized conventional vote-counting
methods because of frequently insufficient power to detect snall
differences even with large sample sizes.

Hovvever, they have derived

methods by which the vote-counting approach can be used to more
accurately estimate the ma.gnitude of effect.

Like combining

statistical significance levels, the usefulness of vote-counting
methods are restricted to situations where little infonnation is
supplied in the errg;>iric research substrate.
The two most connnon analytical approaches used in meta-analysis,
particularly when two groups are co.rrpared, are effect size estimations
and odds ratios.

Effect size estimations are often used when the form

24

of the outcome variable of interest is continuous, whereas cdds ratios
are useful when the outcome variable of interest is dichotomous

(Dernets, 1987; strube & Harbnann, 1983).
For meta-analyses in which the outcome variable of interest is
continuous, effect sizes arrl confidence intervals are estimated for
each study by using the standardized mean difference arrl asscx:::iated
standard deviation, respectively (Hedges & olkin, 1985, chap. 5).

An

overall effect size arrl confidence interval can then be derived by
averaging across individual studies after weighting them by appropriate
factors (e.g., variance, quality) (Hedges

&

Olkin, 1985, chap. 6).

For meta-analyses in which the outcome variable of interest is
dichotomous, cdds ratios arrl asscx:::iated confidence intervals are
derived for each study using the proportion of "successes" in one group
over the proportion of successes in the comparison group.

OOds ratios

different than one indicate an effect arrl the distance from an cdds
ratio of one indicates the magnitude of effect.
arrl

overall cdds ratios

confidence intervals are also derived with weighting individual

studies for the appropriate factors.
It is assumed that effect sizes (when estimated by using
standardized mean differences) arrl cdds ratios are the same across
individual studies (fixed effect mcx:iel).
ho.mo::;eneity can be tested.

This assumption of

Where heterogeneity of effect sizes or cdds

ratios exist, outliers can be identified arrl procedures can be used to
cluster groups of studies with hornoqeneous effect sizes or cdds ratios
(Hedges

&

Olkin, 1985) •

As

an alternative, a random effects model

could be used to account for the degree of heterogeneity (Hedges &
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Olkin, 1985, chap. 9; DerSi.m:mian

&

laird, 1986).

'!he irrportance of

horoc>geneity amorq individual studies is an issue of debate amorq
meta-analysts

am is related to the debate concerning study parameters

for inclusion into meta-analyses (Light, 1987).
Irrlependent of the analytical methods used, the risk of
publication bias usually exists.

Publication bias refers to the

dependency of meta-analyses on published literature that is generally
selective for studies with positive results.

Chan, Sacks,

am

Chalmers (1982) sw::veyed 291 authors of randomized clinical trials

published in medical journals

am found that 41% of the 141 responders

had conducted unpublished studies.

Amorq the randomized clinical

trials conducted by the authors responding to the sw::vey, 77% of those
reportirq positive results were published in contrast to 42% of those
reportirq negative results beirq published.

Therefore, the published

literature on which a meta-analysis is based ma.y not be representative
of all the relevant errpirical research (Begg, 1985).
Methods have been proposed to account for publication bias.

For

situations in which a positive effect has been detected by a metaanalysis, Rosenthal {1979) has derived a formula whereby the number of
unpublished negative trials necessary to make the result of the
meta-analysis null can be estima.ted.

Similarly, L'Abbe et al. (1987)

developed a method of quantifyirq publication bias by simulatirq either
the sample size of one unpublished negative trial or the number of
small negative trials (with a fixed sample size) that would be required
to make the results of a positive meta-analysis negative.

The

estima.tes of Rosenthal am L'Abbe et al. are qualitative in nature in
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that they provide a level of confidence in the positive results of a
meta-analysis, i.e., if only a few negative \ID.published studies would
make the results null there would be less confidence than if hundreds
of unpublished negative trials would be necessary.

In contrast, Begg

(1985) derived a method whereby the magnitude of publication bias for
each study in a meta-analysis is estimated in units of standard
deviation relative to the true mean.

While this method is more

quantitative than those of Rosenthal and L'Abbe et al., it requires
knowledge of the incidence of a specific occurrence (e.g., disease) and
the total number of subjects possible (independent of consent to
participate).

Methods to determine. and adjust for negative publication

bias have not been developed (L'Abbe, et al., 1987)
Reporting results of meta-analyses is similar to reporting
results of empirical research.

However, detail to the descriptive

aspects of the research substrate of a meta-analysis (empiric research)
may have added importance for two reasons.

One

is that meta-analyses

naturally accumulate research methods and procedures related to a
particular research front that can be easily consulted by researchers
investigating future en::ieavors.

Another reason is that reviewers can

more easily detennine the applicability of a meta-analysis from
detailed descriptions (Strube & Hartmann, 1983).

Graphical depictions,

especially of effects size estimates and odds ratios with their
associated confidence intervals are useful adj'lll1.cts to descriptions
(Walker, Martin-Moreno,

&

Artalejo, 1988) •

'Ihe interpretation of meta-analysis results is not a simple
matter.

Interpretations must take into account the general nature of
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meta-analyses.

Iouis et al. (1985) emphasized this point by stating

that:
Although the collection of papers leading to a meta-analysis might
be based on experiments, observational studies, sample surveys, or
other fonns of investigation, the meta-analysis itself is an
observational study with the strengths and weaknesses associated
with that design. (p. 2)
Another ilnportant consideration is that from a "melange of
treatments and mix of patients", quantitative estbnates are derived
that are generally representative of average effects (Wittes, 1987, p.
275) • 'Ihis is generally not a problem for policy makers such as
insurance carriers and governmental agencies who are usually more
interested in the types of average effects generated by meta-analyses.
However, the quantitative estbnates with ''very high degrees of power
does not gainsay the annoying reality that these estbnates of 'average'
effects may be very difficult to apply to specific clinical problems"
(p. 275) •
It is difficult to resist the temptation among those in search of
more specific inforrration to dredge the data within a meta-analysis.
However, they do so at the risk of finding an apparent effect by chance
that is not representative of the true effect (Collins et al., 1987).
'!he peril of post hoc subgroup analysis was demonstrated in the ISIS-1

trial (cited in Collins et al., 1987) of beta-adrenergic receptor
antagonists in acute myocardial infarction.

Subjects born und.er the

astrological sign of scorpio benefitted more from the therapeutic
intervention than those born und.er other astrological signs.

'Ihis

result is more likely due to chance than any biological explanation.
Peto (1987) has thus suggested that "most of the sul:;group analyses from

28

individual trials or from overviews of randomized trials should be just
reported, but not believed" (p. 235), and Collins et al. (1987)
suggest:
Inference about the true size of any effects in subsets may be more
reliable if based indirectly on an overview of all randomized
patients in all trials, rather than on direct examination of only
those subsets. (p. 249)
For use in specific clinical situations, the infonnation derived from
any given meta-analysis will rarely be decisive.

The infonnation

should be viewed in the context of a specific patient or a specific
therapeutic regimen (Wittes, 1987).

It provides some of the

infonnation needed for specific clinical decisions (Yusuf, 1987).
Roles of meta-analysis in clinical medicine.
many roles in clinical medicine.

Meta-analysis plays

One of the roles meta-analysis plays

is one of stabilization of treatment effects.

If individual studies

can va:ry from the true treatment effect as individual subjects can
within a treatment group, meta-analyses can provide better estimates of
the true effect as do group means derived from individual subjects.
Similarly, meta-analyses can counterbalance any "overenthusiasm" that
might be related to a particular outcome (Furberg

&

Morgan, 1987) •

Meta-analysis has been particularly useful in evaluating moderate
treatment effects.

The large sample sizes necessary to detect moderate

treatment effects often result in a series of studies that leave the
research question unresolved.

Properly conducted meta-analyses can

provide adequate power to substantially reduce or eliminate the
equivocation (DarSinonian

&

laird, 1986) •

The Food a:nd Drug

Administration used this approach in approving labelling for aspirin
specifying that it could be used to reduce the risk of death in
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specifying that it could be used to reduce the risk of death in
patients 'Wllo had previously suffered an acute myocardial infarction.
Individual studies had indicated that aspirin might confer such a
benefit, but the effect was sufficiently moderate

an:J

the sample sizes

sufficiently inadequate to reach statistical significance.

However, a

meta-analysis covering these studies subsequently confirmed the benefit
of aspirin in patients previously experiencing acute myocardial
infarction

an:J

the Food

an:J Drug

Administration acted on this

infonnation (Furberg & Morgan, 1987; Hennekens, .Buring, & Hebert,
1987).
Similarly, meta-analysis can be used to analyze certain subgroups
from an aggregate of studies not possible with individual studies.
However, considering the danger in subgroup analysis as previously
described, the use of meta-analysis for subgroup analysis should be
reserved for those subgroups defined a priori.

Where subgroups are

identified in a meta-analysis by data dredging, they should only se:r:ve
as topics for future research (Furberg & Morgan, 1987).
Meta-analysis can

an:J

has been used in the planning of clinical

trials (Hennekens et al, 1987) • Research questions can be generated
from the results of meta-analyses.

For example, in the meta-analysis

of intravenous streptokinase for the treabnent of acute myocardial
infarction (Yusuf et al., 1985), a reduction of mortality was recorded
for patients 'Wllo received treabnent within 24 hours of symptom onset.
Conventional wisdom at the time suggested that only those patients
treated within four to six hours of syrrptom onset would benefit.

To

resolve this discrepancy, a large clinical trial was designed that
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called for trea'bnent with streptokinase during the first 24 hours after
onset of acute myocardial infarction synptam.s (ISIS-2, 1988).

'!he

results confinned the earlier meta-analysis in that benefits were
recorded in all patients treated within 24 hours of synptom onset.
In

planning clinical trials, effect size estimates provided by

meta-analyses can assist in estimating necessary sample sizes.
Meta-analyses can prcxiuce more accurate estimates of effect size than
pilot studies.

'!his was illustrated by two studies assessing the

effects of intravenous beta-adrenergic receptor antagonists in acute
myocardial infarction.

One

of the studies based sample sizes on an

earlier meta-analysis that suggested a 10% reduction in mortality was
possible while the other study based sample sizes on a pilot study that
suggested a 36% reduction in mortality.

'Iherefore, the sample sizes

were substantially different and although each study resulted in the
same ma.gnitude of effect (13-15% reduction in mortality), only the
results of the study based on the meta-analysis reached statistical
significance (Hennekens et al., 1987).
Another role of meta-analysis is pennitting a view of "the forest
through the trees" such that details or patterns that ma.y not have been
discemable in any individual study can be highlighted (Furberg &
Morgan, 1987).

Similarly, meta-analyses can identify "gaps" in current

knowledge, thereby exposing "weaknesses in the errpirical assessment of
a given theory" (Strube & Hartmann, 1983, p. 23).
Criticisms of meta-analysis.

'!he recent introduction of

meta-analysis as a fonnal method of research synthesis has not been
universally embraced.

[Eysenck (1978) has referred to it as
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"mega.-silliness".)

'!he criticisms can be divided into those that are

of non-technical (i.e., enotional) origins and those of more technical
(i.e., methodological) origins.
Some of the non-technical abjections to meta-analysis are rooted
in investigators' ownership of research findings and methodologies they
used to derive them.

It is difficult for some investigators to accept

the fact that rarely do individual studies affect the long-range
perspective of any particular paradigm.

Meta-analyses serve to

errphasize this principle as well as to question individual
methodologies and underlying assumptions (Fiske, 1983; Glass &
Reinhold, 1983).

'Iherefore, investigators unable to dispassionately

view meta-analyses that include their work will likely reject them as a
le;itimate undertaking.
Among clinical medicine researchers, non-technical abjections to
meta-analysis have been raised in the context of its effects on future
research.

Where a consensus has arisen with regard to a particular

mode of therapy, a reluctance to submit subjects to investigations of
alternatives can emerge.

An

example that has been cited (Yusuf, 1987)

is the reluctance of some clinicians to enter post-menopausal women
with Stage II breast cancer to chemotherapy regimens because of an
existing consensus that tamoxifen (a non-chemotherapeutic agent) is
effective even though these clinicians may be uncertain as to the best
approach.
Most of the objections and criticisms directed at meta-analysis
are on methodological grounds and these primarily relate to the
appropriateness of combining study populations, methodologies,· and
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results, as well as using empiric research of varying quality (Glass &
Kliegl, 1983; L'Abbe et al., 1987).

Ct"itics have referred

meta-analysis as comparing apples with oranges; hov.rever, the degree to
which one considers this a significant problem depends on whether one

is viewing the meta-analysis as one pertaining to apples, oranges, or
fruit (Mintz, 1983).
Integrating studies of different degrees of quality, and
especially studies considered lov.r in quality, has generated debate as
to the usefulness of meta-analysis.

Eysenck (1978), in referring to

the use of lov.r quality studies in meta-analyses, evoked an axiom used
in the computer sciences, "gaibage in - ga:r:bage out".

Hov.rever, the

quality of studies can be taken into account by either specifying
methodological requirements in the inclusion and exclusion criteria or
by using quality as a covariate (L'Abbe et al., 1987).
smith, Blackburn, Silvenran, Schroeder, Reitman,

&

Olalmers,

Ambroz (1981) have

developed a method by which the quality of a study can be quantified
and weighted accordingly.

'Ihe seriousness of study design flaws could

then be assessed by the degree in which they correlate with effect
size.

Glass and Kliegl (1983) have thus countered Eysenck's contention

by suggesting that differences in study quality handled appropriately
can result in "garbage in - information out".
Pooling results of different studies using different
methodologies, involving different subject types, and done at different
times has long been debated among statisticians.

'Ibis debate has been

appropriately extended by critics to meta-analysis.

(Proponents of

meta-analysis have suggested that narrative reviews suffer the.same
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problems (Strube & Hartmann, 1983; '!hacker, 1988).]

However,

techniques such as sensitivity analysis and. weighted regression have
been applied to meta-analyses to partially take the heterogeneity of

methods, subjects, and. time into account (L'Abbe et al., 1987).
Meta-analysis is still evolving and. methods to inprove methodological
approaches that address same of the current limitations are under study
('Ihacker, 1988).
Slm:lmary.

Meta-analysis refers to a group of methodologies that

can be used to combine related empiric research to arrive at
conclusions not possible by reviewing individual studies, or improving
generalizations of individual studies.

Meta-analysis is distinguished

from the traditional narrative review in that statistical methodologies
are applied to derive "objective" conclusions whereas narrative reviews
are more subjective.

However, meta-analysis is not a substitute for a

definitive study in which conclusions are usually based on a more
homogeneous sample than possible with a meta-analysis.

Therefore, a

major role of meta-analysis is where the appropriate definitive study
is not logistically feasible or where there is uncertainty as to
whether such a study is warranted.
Meta-analysis is not without its critics; it is perhaps best
described as an evolving entity.

To

assist the evolutionary process,

L'Abbe et al., (1987) have suggested that a consensus conference be
convened to develop stand.a.rd. protocols.

They, among others (Stube &

Hartmann, 1983), have also suggested that central registries of ongoing
trials specific to well-defined content areas (such as the National
Institutes of Health or World Health Organization for clinical
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medicine) be establishe::i as a means to reduce the sarrpling bias known
to plaque meta-analyses.

In

addition, brief summaries might be made

available to assist investigators in assessing whether certain studies
are relevant.

ca.Ils have also been issue::i for continued investigation

into statistical methods that will address the shortcomings of
meta-analysis, development of methods to assess their quality, and
better reporting of research reports (Strube & Harbnann, 1983; Thacker,
1988).

Strube

&

Harbnann have gone one step further in proposing "a

generative function for meta-analysis that is an extension of the
pre::iictive function" (p. 24)
Although many important and useful meta-analyses relate::i to
clinical medicine have been conducted, its acceptance in clinical
medicine has been slO'iAT in coming.

HO'iATever, the number of meta-analyses

publishe::i related to clinical medicine is steadily increasing and
there is evidence that meta-analytical techniques will eventually be
require::i as :part of all literature reviews.

METHOD

General Approach
'!he method by which the comparative nephrotoxicity of gentamicin
and tobramycin was assessed. using previously completed studies centered

on the meta-analytical concept of "effect size".

Effect size generally

represents the magnitudes of difference between pa.irs of trea'bnent
conditions.

'!bus, an effect size of zero suggests that there is no

difference between a pa.ir of trea'bnent conditions (i.e., gentamicin and
tobramycin nephrotoxicity) while an effect size of either less than or
greater than zero suggests that a difference exists.

'!he greater the

effect size (independent of sign), the greater the magnitude of
difference between trea'bnent pa.irs (Glass et al., 1981).
'!here are several methods by which to estimate effect size.

In

the meta-analysis reported here, where the comparative nephrotoxicity
of gentamicin and tobramycin could be evaluated with a continuous
variable (i.e., degree of nephrotoxicity), effect sizes were estimated
by directly calculating standardized mean differences (referred to in
this pa.per as the parametric analysis) • Where the comparative
nephrotoxicity could only be evaluated with a dichotomous variable
(i.e., nephrotoxicity occurred or not), a modified vote-counting
proce:::'iure was used to estimate effect sizes (Hedges & Olk.in, 1985).
[Although Hedges and Olk.in refer to the mcx:lified vote-counting method
as "pa.rtially parametric" (p. 47), in the meta-analytic procerlure
reported here, it is referred. to as the nonparametric analysis.]
overall, the meta-analysis of the comparative nephrotoxicity of
gentamicin and tobramycin involved three distinct procedures.
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First,
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searching and retrieving the relevant literature; second, screening

the retrieved literature for inclusion and exclusion criteria; and
third, analyzing the data in the literature :rrte!eting the screening

criteria.
Literature Search
Both electronic and manual searches of the medical literature
were conducted to locate and retrieve published and unpublished studies
related to the comparative nephrotoxicity of gentamicin and
tobranwcin.

In addition, the manufacturers of gentamicin (Schering,

Inc.) and tobranwcin (Eli Lilly, Inc.) were contacted in order to

retrieve any related unpublished infonration they might have had on
file.
Electronic literature search.

MEDLINE [MEDIARS (Medical

Literature Autorna.ted Retrieval System) online], International
Fharmaceutical Abstracts (IPA), Embase, and Dissertation Abstracts
Online were searched electronically.

With the exception of

Dissertation Abstracts Online, the published controlled vocabularies
for each of the databases searched electronically were used to find the
most appropriate te:rrns for the search strategy.

All searches were

limited to htnnan studies published in the English language.
MEDLINE is an electronic database of predominantly clinical
medicine literature produced by the National Library of Medicine.

It

is derived from approximately 3, 000 biomedical journals published
worldwide beginning in 1966

(Kruse, 1983).

'!he te:rrns used to search

MEDLINE were, "kidney failure, acute" or "kidney tubular necrosis,
acute" with both "gentamicin" and "tobranwcin11 (National Library of
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Medicine, 1987).
Embase

is an electronic database of predominantly clinical

medicine literature produced by Elsevier Science Publishers.

It is

derive::i from approximately 4, ooo biomedical journals published
worldwide since 1975 (Kruse, 1983).

'Ihe terms used to search Embase

were, "acute renal failure" with both "gentamicin11 and "tobramycin"
(E:x:cerpta Medic.a, 1984).
IPA is produced by the American Society of Hospital Fhannacists
and is an electronic database derive::i from over 600 journals primarily

relate::i to phannacy practice publishe::i worldwide since 1970 (Kruse,
1983).

The terms used to search IPA were, "kidney failure" with both

"gentamicin" and "tobramycin" (Tousignaut, 1987) •
Dissertation Abstracts Online is produced by Dissertation
Abstracts International and is an electronic database comprised of
nearly every doctoral dissertation dating back to 1860 (Perry, 1986).
It was searc:he::i to determine whether relevant inforn:ation regarding the
comparative nephrotoxicity of gentamicin and tobramycin has been
subject of a doctoral dissertation that had not been otheJ::Wise
publishe::i.

The terms used for a free-text search of Dissertation

Abstracts Online were, "gentamicin", "tobramycin", and
"nephrotoxicity".
Manual literature search.

The manual literature search consisted

primarily of scanning the reference lists of the studies retrieved from
the electronic search.

In addition, bibliographies provided by the

drug manufacturers contacted were scanned for appropriate citations.
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Inclusion and Exclusion Criteria·
'.Ihe inclusion criteria for entry of individual studies into the
meta-analysis were different de:pending on the method used to estimate
effect size.

'.Ihe exclusion criteria were not similarly affected.

Parametric analvsis.

'.Ihe criteria for the inclusion of studies

that evaluated the ccnnparative nephrotoxicity of gentamicin and
tobrarnycin using a continuous variable were (a) rnethcxis and results
were in the English language; (b) investigations were limited to blil'!laJl
subjects; (c) there were at least two inclependent groups in each study,

one of which received gentamicin and the other tobrarnycin; (d) renal
function was measured by either serum creatinine concentrations or
creatinine clearances; and (e) means and measures of variance (i.e.,
standard deviation, standard error, variance, or range) of either
continuous measure of renal function were reported.
Sennn creatinine concentrations and creatinine clearances were
the continuous variables selected as the basis for estimation of effect
sizes because these have been the laboratory values most often used to
measure nephrotoxicity in the ccnnparative studies involving gentamicin
and tobrarnycin (Schentag, 1983).

Creatinine is a metabolic prc:duct

prcrluced in muscle that is released at a relatively constant rate.

In

the absence of renal failure, excretion of creatinine through the
kidneys occurs at a rate (creatinine clearance) approxinately that of
blcx:x:l filtered by the kidneys [glomerular filtration rate (GFR)].
'.Ihus, renal function or changes in renal function can be measured by
creatinine clearance.

I.og"istical considerations, however, frequently

prohibit accurate measurement of creatinine clearance directly;
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therefore, serum creatinine concenpation is often used.

Since

creatinine is produced at a relatively constant rate and is eliminated
al.most entirely by excretion through the kidneys, a change in renal
ftmction can be approximated by corresponding chan<Jes in serum
creatinine (Ravel, 1978).

Serum creatinine concentration and

creatinine clearance are therefore necessarily related, and in fact,
serum creatinine concentrations may be more sensitive to changes in
renal function than creatinine clearance (Morgan, & Will, 1983).

Both

are considered. late markers of aminaglycoside nephrotoxicity (Schentag,
1983).
'!he exclusion criteria included (a) studies that included data
reported in another study, and (b) studies not obtainable either
directly or by available intra-libracy loan programs.
Nonparametric analysis.

'!he inclusion criteria for studies that

compared the nephrotoxicity of gentamicin and tobramycin with a

dichotomous variable were same as those for studies in the parametric
analysis except that the incidence of nephrotoxicity for both the
gentamicin groups and tobramycin groups had to be reported instead of a
continuous measure of renal function.

In

nephrotoxicity used had to be specified.

addition, the definition of
'!he exclusion criteria were

the same as those for studies in the parametric analysis.
Da.ta Collection
From

the lists of references available as a result of the

literature searches, studies were identified that appeared related to
the comparative nephrotoxicity of gentamicin and tobramycin.

'Ihese

references were obtained and screened according to the inclusion and
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exclusion criteria.

'Ihose studies. that met the screening criteria were

entered into the meta-analysis and se:parated into (a) studies to be
used for the parametric analyses, (b) studies to be used for the
nonparametric analyses, and (c) studies that could be used for both the
parametric and nonparametric analyses.
Data Analysis
Parametric analysis.

'Ihe estimated effect size for each study

that met the screening criteria for studies that compared gentamicin
and tobramycin nephrotoxicity using a continuous measure of renal

function was derived by the standardized mean difference,

(_xG - XT) /§,

(1)

'Where _xG and XT are the mean continuous measures of renal function
(serum creatinine concentration or creatinine clearance) for the
gentamicin and tobramycin groups, respectively, and

§

is the pooled

sarrple standard deviation as derived by,
(DG _ 1) (§G)2 + (DT _ l) (§T)2
(2)

§=

DG + DT - 2
'Where

nG

and

nT

are the gentamicin and tobramycin group sample sizes,

respectively, and §G and §T are the standard deviations of the
continuous measures of renal functions for the gentamicin and
tobramycin groups, respectively.

Pooled estimates of sarrple standard

deviations were used because equal PJpulation variances for the
gentamicin and tobramycin groups could be assumed. (Hedges & Olk.in,
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1985, pp. 78-79).

Where the range of :measurements of renal function

were providerl in place of standard deviations, the standard deviation
was approximaterl by§

=

rarqerJij.

Where the standard error of the

renal function :measurements were providerl in place of the standard

deviation, the standard deviation was deriverl by§ = standard error -{D

(Littenberg, 1988).
'Ihe estimate of effect size as derived by F.quation 1 is
associaterl with a small sample bias approx:imaterl by 3cJ/(4N - 9); thus,
as the sample size increases, the bias is reduced.

To

adjust for this

bias, the effect size deriverl by F.quation 1 was multiplierl by the

= (1 - (3/{4!1! - l})], where

correction factor J(!l!)

(Herlges & Olkin, 1985, pp. 79-80).

!l!

= [(DT

+ DG) - 2]

'Ihus, the effect size (g) for each

study was estimaterl by

g =

(3)

(J!l))

'Ihe large sample distribution of F.quation 3 approximates
nonnality if nG and nT increase at the same rate.

'Ihe estimaterl

variance of g is thus,

a-2

(g)

=

+

( 4)

and the 95% confidence intervals are then,

cJ u = 9 + c cv/2 G(9) ,
'Where

'1 is the population effect size estimaterl by g and C «/2

(5)

is the

two-tailerl critical value of the standard nonnal distribution (Herlges &
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Olk.in, 1985, pp. 85-88).

Therefore, according to Equation 3, an estimated effect size
greater than zero suggests that gentamicin is associated with
nephrotoxicity to a greater degree than tobramycin.

Conversely, an

estimated effect size less than zero suggests that tobramycin is
associated with nephrotoxicity to a greater degree than gentamicin.
Otherwise an estimated effect size approximating zero suggests that
there is no significant difference in the degree of nephrotoxicity
between

the two agents.

Confidence intervals can also be used for interpretation.

A 95%

confidence interval as derived by F.quation 5 that is comprised of
values only greater than zero suggests that gentamicin is associated
with nephrotoxicity to a greater degree than tobramycin.

Conversely, a

95% confidence interval comprised of only values less than zero

suggests that tobramycin is associated with nephrotoxicity to a greater
degree.

Other-wise, 95% confidence intervals that include zero

suggest that there is no significant difference in the degree of
nephrotoxicity between the two agents.
To derive an estimated effect size for the series of comparative
trials, a weighted linear combination of the individual effect sizes
was used (.9v,

= 11).91

+ •.. +

weights summing to unity).

~k,

where 111 •.•

!Y'}{

are nonnegative

Weights were assigned based on the inverse

of the effect size variances,

(6)
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'Ihe weighted estimate of

J+

(.9+) based

on the sarrple estimate of c) (g)

to derive the weights for each study was

(7)

(Hedges & olkin, 1985, pp. 109-111).
Like the effect size estimates for individual studies, the

weighted effect size estimate for the series of studies

(.9+)

approximates nonnality; thus, confidence intervals forJ' + can J::e
derived using g+, assuming

nT

and

nG increase in size at the same rate.

'Ihe confidence intervals for the estimated effect size for the series
of studies were then,

cJ L = .9+ -

C d./2

~ (.9+) '

J u = .9+ + c d./2 6

(8)

(.9+) '

where C # 2 is the two-tailed critical value of the standard nonnal
distribution and G~.9+) is derived by

0- 2(d+) ~
(Hedges

&

i~"'' .,_1 . )-1

(

(j (91)

(9)

olkin, 1985, pp. 112-113).

'Iherefore, like estimations of effect size for individual
studies, an estimated effect size for the series of studies that is
greater than zero suggests that gentamicin is associated with
nephrotoxicity to a greater degree than tobramycin, and conversely, an
estimated effect size less than zero suggests that tobramycin is
associated with nephrotoxicity to a greater degree than gentamicin.
otherwise, estimated effect sizes approximating zero suggest there is
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no significant difference in the degree of nephrotoxicity between the
two agents.
Confidence intervals can be used to make similar
interpretations.

A 95% confidence interval carrprised of only values

greater than zero suggests that gentamicin is associated with
nephrotoxicity to a greater extent than tobramycin and an estimated
effect size 95% confidence interval carrprised of only values less than
zero suggests that tobramycin is associated with nephrotoxicity to a
greater extent than gentamicin.

otherwise, 95% confidence intervals

that include zero suggest no significant difference in the degree of
nephrotoxicity between the two agents.
In order to make inferences from the aggregate effect size
estimate, (Q+), the assumption of homogeneity of effect sizes among the
population effect sizes nrust be met (i.e.,

cJ 1 =J2 = ...

=Jk>.

Hamcx;Jeneity of effect sizes was tested by using the Q statistic,

k

Q

=

(gi - Q.+)2

L'*

,.t.. 1 v

--

(10)

2(d·)
-1

wherein Q has an asyrrptotic chi-square distribution with k-1 degrees of
freedom when there is homogeneity of population effect sizes in the
series of k studies.

Therefore, if

Q

exceeds the .05 percent critical

value of the chi-square distribution with k-1 degrees of freedom, the
null hypothesis of homogeneous population effect sizes is rejected
(Hedges & olkin, 1985, pp. 122-123).

A group of homogeneous studies

was identified by withdrawing studies until the homogeneity assumption
was met as defined by the Q statistic.
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Sensitivity analyses were conducted to detennine the relationship
of certain variables with estimated effect size.

'!he effect of

hOillCXJeneity on the overall effect size estimate was detennined. by
with-drawing individual studies until hOillCXJeneity was satisfied. by the
Q

statistic.

Relationships of individual study characteristics with

estimated. effect size were investigated using sirrq;>le linear regression
techniques (God.frey, 1985) with Systat (Wilkinson, 1985).

Independent

variables selected. were those in which differences of clinical
significance existed between the gentamicin and tobramycin groups and
included. mean age, mean durations of therapy, initial renal function,
and incremental changes in renal function.

In

addition, whether the

studies were blinded. or randomized. was investigated as well.

'Ibe

regression analyses were restricted. to the hOillCXJeneous group of
studies.
Nonparametric analysis.

'Ihe dichotomous variable used. in studies

comparing the nephrotoxicity of gentamicin and tobramycin was whether
nephrotoxicity occurred. or not according to arbitrary criteria.

To

estimate the effect size of the difference in nephrotoxicity of
gentamicin and tobramycin in this series of studies, the :mcd.ified.
vote-counting method of Hedges and Olk.in (1985, chap. 4) was employed..
'Ibis method is based on the proportion of studies within a series of k
studies in which the difference between groups reach statistical
significance.
To

estimate the effect size of a series of k studies using the

vote-counting method of Hed.ges and Olk.in (1985, chap. 4), each group
within each study and between studies must be equal in size, (i.e, the
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number of patients in the gentamicin group must be equal to the number
of patients in the tobramycin group arrl all studies must have the same
numbers of patients in each treatment group) •

However, an average

value can be derived using the square mean rcx:>t (SMR),

(11)

where n is the equivalent sample size in each treatment group arrl k is
the number of studies in the series (Hedges & Olkin, 1985, pp. 67-69).
The mcxtified vote-counting method to estimate effect size also
requires that differences between groups were tested statistically by

using the

.t

distribution.

To

satisfy this criteria, the differences in

proportions of patients considered nephrotoxic in the gentamicin group
versus the tobramycin group in each study were tested statistically
using the Relative Deviate Test which prOO.uced
Sharnpo, 1981).

z

scores (O'Brien &

Since the average sample size (DSMR) exceeded 30, the£!

distribution approximates the t distribution.
critical

z

A difference reaching a

score of 1.96 (.p = .05, two-tailed) was considered

statistically significant.
The estimated effect size of the difference in gentamicin arrl
tobramycin nephrotoxicity based on the proportions of patients
considered nephrotoxic was derived by

...

P.os<e>

=

ufk,

(12)
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where U/k is the proportion of studies in which the difference between
the gentamicin and. tobramaycin groups reached statistical significance
at the .05 level (Hedges & Olk.in, 1985, pp. 52-53). A table giving
....
P.05(8) as a function of effect size and. the corrnnon sample size (DSMR)
was used to derive the estimated effect size for the series of studies
(pp. 60-61) •

Confidence intervals for the proportion of studies in which the
difference between the two treatment groups reach statistical
significance at the • 05 level were computed by,

Pr. = ~

-

c

- /£(1 - §)
oly'2

v.

k

=

p+ c

J./2

~(1 -

v-

I;

Pu

k

p)
,

(13)

where p is the proportion of studies in which the difference in
proportion of gentamicin and. tobramycin patients considered nephrotoxic
reached statistical significance, c o<fl is the two-tailed critical
value for the stand.ard normal distribution, and. k is the number of
studies in the series (Hedges & Olkin, 1985, p. 54)

From these values,

the same table used to derive the mean estimated effect size is used to
derive the estimated effect size confidence interval.
Because with this method an effect size can be estimated only for
a series of studies, sensitivity analyses ilwolving relationships of
individual study characteristics with estimated effect size cannot be
.ilwestigated.

Hc:Mever, the effect of specific studies on the study

series estimated effect size was .ilwestigated by removing individual
studies or grouping others.

RESUI1I'S

AND CONCI.DSIONS

Literature Searches
The literature searches identified. 36 studies in which the
nephrotoxicity associated. with gentamicin and tobramycin was compared..
After retrieval and screening each study according to the inclusion and

exclusion criteria, 18 (50%) were eligible for analysis.

All of the

studies were published. between 1976 and 1985 (Table 1).
Among the clinic.al trials that were not included. in the

analysis, three were excluded. because they were not comparative, four
because renal function was not assessed, one because neither a
continuous measure of renal function nor the proportion of patients
considered nephrotoxic were reported., and eight because the same data
were reported. in other studies included. in the analysis.

In

addition,

one study identified. was not obtainable and one was not published. in
the Eng'lish language.
Descriptive Data
Of the 18 studies included. in the analyses (Table 1), 11 provided
documentation of renal function sufficient for the parametric analyses
(i.e., 10 reporting sennn creatinine concentration and one creatinine
clearance).

Two

of these studies were derived. from one published.

article (Matzke, Iucarotti,

&

Shapiro, 1983) • 'IWo separate independent

investigations were conducted. in this study; and therefore, represent
two of the 18 studies included. in the meta-analysis (Study 10 and Study

11).

Seven of the studies provided. only enough infonnation for the

nonparametric analyses.

However, six of the studies included. in the
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Table 1
Clinical Trials Included in Analysis

Study
N\.:aTber

First
Author

Year
Published

Source

Clinical Trials Included Cilly in Pararretric Analysis
1

Madsen

1976

Jarrnal of Infectious Disease

2

Kahlneter

1978

Journal of Antimicrobial Chem::rt:her?PY

3

Goodwin

1979

Proceedings of 11th International Congress of
Cherotherapy

4

5

Itsarayoun:JyUen
Donta

Table continued

1982

Pediatric Pharmacology

1985

Antimicrobial Agents and Charotherapy

Table 1 (continued)
Clinical Trials Included in .Analysis

Study
Nmber

First
Author

Year
Published

Source

Clinical Trials Included in Both Parairetic and Nonparairetic .Analyses
6

Smith

1980

New Englarrl Joornal of Medicine

7

FOI¥J'

1981

Journal of Ant:imicrcbial Otarotherapy

8

Schentag

1981

Antiroicrcbial

9

Feig

1982

Journal of Anti.micrcbial Otarotheraei:

10

Matzke (A)a

1983

Anerican Journal of Ne}'.:hrology

11

Matzke (B)a

1983

Anerican Journal of Ne:Efu:ology

~ents

and Otarotherapy

Table continued

IJ1
0

Table 1 (o::intinued)

Clinical Trials Included in Analysis

Sbxly
Nmber

First
.Author

Year
Published

Source

Clinical Trials Included in Only Nonpararretric Analysis
12

Walker

1976

Journal of Infectious Disease

13

Wade

1978

Lancet

14

Kunin

1980

Joornal of the hrerican Medical Association

15

Keys

1981

Mayo Clinic

16

Brown

1982

Antimicrobial Agents and Olarotherapy

17

Panrorl:x:>

1982

Biq::hannaceutics and Drug Distribution

18

Fee

1983

Review of Infectious Disease

Pr~s

~ Matzke stuiy iocluded b.io separate analyses and are thus labeled as Matzke

(A) and Matzke (B) , respectively.
1.11

I-'
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para-metric analysis also provided. the proportions of patients
considered. nephrotoxic in each treatment group so these studies were
also included. in the nonparametric analysis.

'lli.erefore, a total of 13

clinical trials were included. in the nonparametric analyses.
'lli.e 18 studies included. in the meta-analysis involved. a total of
967 treatment courses of gentamicin and 876 treatment courses of
tobramycin.

Of the 11 studies used in the parametric analyses, there

were 525 courses of gentamicin and 523 courses of tobramycin.

Of the

seven clinical trials that could only be used for the nonparametric
analyses, there were 442 courses of gentamicin and 353 courses of
tobramycin.

When the clinical trials that could be used for both

analyses were combined. with those that could only be used for the
nonparametric analyses, there were 862 courses of gentamicin and 758
courses of tobramycin.
As shCMn

in Table 2, the sample sizes were generally equivalent

in each treatment group for nearly all the clinical trials included. in
the analyses.

'lli.e two exceptions were Study 4 (Itsarayoungyuen, Riff,

Schauf, Hamilton et al., 1982), and Study 17 (Pancorbo, Compty,
Heissler, 1984).

&

In Study 4, 20 patients received. gentamicin and 30

patients received. tobramycin due to a randomization scheme designed. to
assign patients to gentamicin or tobramycin in a 2: 3 ratio.

'lli.e basis

for this randomization scheme was that because gentamicin had been
previously studied. more extensively in the patient population
randomized. (neonates), it was desirable to randomize more patients
into the tobramycin group.

In

Study 17, 125 patients received.

gentamicin and 39 patients received. tobramycin.

In this study,

Table 2
Descriptive Data of Clinical Trials Included in Analyses

To~

Seruip

Dose
G
T

Cone.
G

T

Clinical Trials Included cnly in Pararretric Analysis
1

36

36

mt1

NR

NR

NR

7

7

NR

NR

106

106

2

18

19

59

67

3.68

2.57

21

15

NR

NR

79

103

3

22

22

NR

NR

2.32

2.88

15

15

2.1

2.2

149

157

4

20

30

0.004

0.004

0.67

0.6B

8

B

NR

NR

97

BB

5

9

11

2.05

2.60

9

9

NR

NR

177

108

55

59

Table continued
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Table 2 (continued)
Descriptive Data of Clinical Trials Included in Analyses

Pati~t

Tota~

hje

G

T

~
Cone.

Dose
G
T

G

T

Clinical Trials Included in Both Parametic and Nonpa.rametic Analyses

6

72

74

5B

59

1.90

1.92

6

6

2.8

2.5

150

159

7

102

103

51

55

1.99

1.83

B

8

1.6

1.3

BB

97

8

137

121

67

66

1. 70

1.70

10

11

1.6

1.4

51*

51

9

25

29

57

57

NR

NR

8

9

1.1

1.4

85

7B

10

49

49

61

64

1.73

1.81

10

11

1.4

1. 7

95

104

11

50

48

62

62

1.99

1.98

10

11

1.4

1.5

109

103

Table oontimled

Table 2 (continued)
Descriptive Data of Clinical Trials Included in Analysis

Totati
Dose

Pati~t

h:je

G

T

G

Sennp

Cone.
T

G

T

Creatinineg
G
T

Clinical Trials Included in Only Nonpararretric Analysis
NR/NSi NR/NS

NR

NR

7

7

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

55

57

2.1

2.2

10

11

NR

NR

NR

NR

12

51

45

NR

NR

19

14

1.6

1.9

NR

NR

103

96

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

17

125

39

59

59

1. 7

1.8

9

10

1.4

1.2

128

131

18

87

86

44

46

1.9

2.4

9

11

1.0

0.9

NR

NR

12

40

40

13

43

47

NR

14

29

33

15

15

16

= gentamicin. b.r = t.oQramycin. ~ age in years. ~ total dose in grams.
duration in days. ~ trough serum concentrations in milligrams/liter.
9Mean serum creatinine (milligraws/liter) except for Stud¥ 8 which is creatinine
clearance (milliliters/minute). A'NR = data not reported. ""NR/NS = data not reported but
difference described as not statistically significant.

8G
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01

56
patients we.re not assigned to receive gentamicin or tobramycin by
random allocation.

'lbe drug prescribed was detennined by the prima:ry

care physician and at the time of this study, the.re was an apparent
preference for gentamicin at the institution where this study was
conducted..

'lbe mean patient age was reported for both the gentamicin and
tobramycin groups in 13 studies (72%).

Although the mean patient age

for both grou,ps was not reported in Study 12 (Walker & Gentry, 1976),
it was noted that the difference in ages did not reach statistical
significance.

With exception of Study 4 (Itsarayoungyuen et al.,

1982), which involved neonates, all the studies involved mostly adults.
'lbe mean patient ages for both treabnent grou,ps generally occurred in
the fifth to seventh decades.

Within the studies in which mean patient

ages we.re reported, mean ages we.re always similar for the gentamicin

and tobramycin grou,ps (Table 2) .
'lbe mean total amount of gentamicin and tobramycin used was
recorded in 12 studies (67%).

Excluding Study 4 (Itsarayoungyuen et

al. , 1982) , which involved neonates, the mean total amounts of
gentamicin and tobramycin used ra.ng-ed from 1.69 to 3.68 grams and 1.70
to 2.88 grams, respectively.

Within the studies reporting the mean

amount of gentamicin and tobramycin used, the amounts were very similar
for each group with the exception of two studies.
(Kahlmeter, Hallberg,

&

In Study 2

Kanune, 1978), the mean total dose of

gentamicin was 3.68 grams carrpared to 2.57 grams of tobramycin.
Study 18 (Fee, Vierra,

&

In

lathrop, 1978) , the mean total dose of

gentamicin was 1. 9 grams carrpared to 2. 4 grams of tobramycin (Table 2) .
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'!he mean duration of gentamicin and tobramycin therapy was
reported in 16 studies (89%).

'!he mean duration of therapy ra.J1<:1ed from

six to 21 days and six to 15 days for gentamicin and tobramycin,
respectively.

With the exception of two studies, the mean duration of

therapy for gentamicin and tobramycin were nearly identical.

For lx>th

exceptions, gentamicin was used for a longer period of time than
tobramycin.

In Study 2 (Kahl.meter, Hallberg,

& Karnrne, 1978), mean

gentamicin use duration was 21 days as compared to a mean of 15 days
for tobramycin use.

In Study 15 (Keys, Kurtz, Jones, & Muller, 1981),

mean gentamicin use duration was 19 days compared to a mean of 14 days
for tobramycin use.

In Study 2, the longer mean duration of therapy

for gentamicin correlated with the larger mean total dose reported.
Mean total dose for Study 15 was not reported (Table 2) •
Mean trough gentamicin and tobramycin serum concentrations were
reported in 10 studies ( 56%) •

Mean trough serum concentrations in the

studies in which they were reported ra.J1<:1ed from 1.0 to 2.8 milligrams/
liter and 0.9 to 2.5 milligrams/liter for gentamicin and tobramycin,
respectively.

Within each reporting study, the gentamicin and

tobramycin trough serum concentrations were very similar (Table 2) .
'!he mean serum creatinine concentrations prior to initiation of
therapy were reported for lx>th the gentamicin and tobramycin groups in
11 studies (61%) and the mean creatinine clearance prior to initiation
of therapy was reported in one (6%).

'!he mean initial sen.nn creatinine

concentration ra.J1<:1ed from 79 to 177 micromoles/liter and 78 to 159
micromoles/liter in the gentamicin and tobramycin groups, respectively.
Within each of the reporting studies, initial serum creatinine
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concentrations were similar for both gentamicin and tobramycin groups
with the exception of Study 5 (D:>nta & Lembke, 1985) in 'Which the
initial serum creatinine concentration for the gentamicin group was 177
micromoles/ liter corrpared to 108 micromoles/liter for the tobramycin
group.

Sen.mt

creatinine concentrations considered to be indicative of

nonna.l renal function range from 71 to 177 micromoles/liter (Ravel,
1978).

Only the gentamicin group in Study 5 reached. the upper limit.
In

study 8 (Schentag, Plaut, & Cerra, 1981) creatinine clearance

was used. instead of serum creatinine concentrations.

'Ihe initial

creatinine clearance for both the gentamicin and tobramycin groups was
51 milliliters/minute (Table 2).

Creatinine clearances indicative of

nonna.l renal function are between 90 and 120 milliliters/minute;
however, nonna.l values decrease with age (Ravel, 1978).

'Ihus, Study 8

differed. from the others in that both groups had compromised renal
function at the initiation of therapy.

'Ibis is consistent with the

greater severity of illness among the patients in Study 8 than the
other studies.
'!he incidence of neph:rotoxicity for each treatment group was
recorded. in each of the 13 studies included. in the nonparametric
analysis according to the definition of neph:rotoxicity established. by
the investigators of each study.

'Ihe definitions of neph:rotoxicity

used. in each of these studies are listed. in Table 3.

Although the

definitions varied. among studies, they were generally similar.
Arong the 13 studies included. in the nonparametric analysis
(Table 4), the neph:rotoxicity incidence ranged. from 4 to 55% and 2.5 to
58% for the gentamicin and tobrarnycin groups, respectively.

'Ihe
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Table 3

Definitions of Netfu:ot.oxicity in Nonpararretric Analysis

Sttrly
Nurrber

Definition of Neffuotoxicity

Stu:ties Included in Both Pararretic and Nonpararretic Analyses
6

SCRa increase > 44 if initial SCR < 265 or,
SCR increase >-88 if initial SCR > 265

7

SCR increase > 44 if initial SCR < 265 or,
SCR increase } 88 if initial SCR > 265

8

SCR increase > 44

9

SCR increase > 27

10

SCR increase > 44 if initial SCR < 177 or,
SCR increase> 30% if initial SCR > 177

11

SCR increase > 44 if initial SCR < 177 or,
SCR increase} 30% if initial SCR > 177

Studies Inclooed in cnly Nonpararretric Analysis
12

SCR increase

13

SCR increase > 35 if initial SCR < 265 or,
SCR increase } 80 if initial SCR > 265

14

SCR increase > 33%

15

Iothalama.te decrease to < 14% of initial

16

SCR increase > 35

17

SCR increase > 30%

18

Final SCR > 133 with decrease in CRCL > 33%
or, SCR increase> 88 if initial "abnonnal"

~CR = serum creatinine c:onoantratian in micraroles per liter.
CRCL = creatinine clearance in milliliters per minute.
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Table 4

ca:rponents of Nonparametric Bffeet Size Esti.ma.tions

Study

Z-Score

Nurri:ler

Difference
Statistically
Significant

Stu:lies Included in Both Pararnetic and Nonpa.rarnetic Analyses
6

19/72

9/74

2.8

Yes

7

8/102

7/103

0.3

No

8

51/137

27/121

2.5

Yes

9

10/25

8/29

1.0

No,

10

5/49

9/49

-1.1

No

11

4/50

8/48

-1.3

No

Stt:rlies Included in Only Nonparametric Analyses
12

7/40

2/40

1.8

No

13

13/43

11/47

0.8

No

14

16/29

5/33

3.3

Yes

15

6/13

7/12

-0.9

No

16

5/103

2/96

1.1

No

17

5/125

1/39

0.4

No

13/86

1.8

No

18

22/87

~of ~'!=ients neph;:ota>d.c/total.nunt:er of patients.
G

= gentamicin

group •.. '""l.'

= t.obrarqyci.n

group.
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incidence of nephrotoxicity was lower for the gentamicin group in three
of the studies and higherin the other 10.

'Ihe difference in the

incidence of nephrotoxicity between groups reached statistical
significance in three studies, in all of which a lower incidence was
recorded for the tobramycin groups.

'Ihe greatest differential between

the two groups in any one study was recorded in Study 14 (Kum.in, 1980)
in which the incidence of nephrotoxicity for the tobramycin group was
15% corrpared to 55% for the gentamicin group.
'Ihe ranges of nephrotoxicity for both groups remained the same
when the seven studies that could only be used in the nonparametric
analysis were considered.

In only one study was the incidence of

nephrotoxicity lower for gentamicin than tobramycin.

Also in only one

study did the difference in the incidence of nephrotoxicity between the
treatment groups reach statistical significance (Table 4).
Parametric Analyses
Effect size estimations.

'Ihe corrp:ments used to estimate effect

sizes for each study based on a continuous measure of renal function
are listed in Table 5.

'Ihe estimated effect sizes derived, and their

respective variance terms (stan:iard deviations and 95% confidence
intervals), are listed in Table 6.

Figure 1 is a plot of the estimated

effect sizes and associated 95% confidence intervals for each study.
'Ihe estimated effect sizes ranged from

-o. 887

to 1. 666.

Four of

the 11 studies were associated with estimated effect sizes of negative
values (suggestin:';J tobramycin is associated with nephrotoxicity to a
greater degree than gentamicin) and the remainin:';J seven studies were
associated with estimated effect sizes of positive values (suggesti.:n;J
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Table 5

Carponents of Effect Size calculations in Pararretric Analysis

Study
Nuni:er

St:an:Ja:cd

Pooled

Correction

Deviation
G
T

Staxxla:rd

Factor

Deviation

[J(m)

1

114

111

26.5

26.5

25.5

0.989

2

100

109

15.2

31.0

24.6

0.978

3

323

157

133.3

38.8

98.l

0.982

4

124

88

39./5

48.4

45.1

0.984

5

207

126

275.7

59.7

189.1

0.958

6

186

168

150.2

152.3

151.2

0.995

7

203

230

28.0

31.3

29.8

0.996

ad

41

50

27.0

34.0

30.S

0.997

9

100

78

43.3

23.9

35.0

0.957

10

125

134

40.4

35.4

38.0

0.992

11

148

149

30.0

122.5

88.3

0.992

~tial s~ creatinins! concentratic;ms in miC!)pO~~/liter.

G = gentamicin group. ,. = tabrareycin group.
creatinine clearance in milliliters/minute.

""Initial

J
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Table 6
Estimated Effect Sizes in Pararretric Analysis

Study
Nurcber

Estimated
Effect
Size

Standard
Deviation

1

0.131

0.236

-0.332 -

0.593

2

-0.334

0.331

-0.983 -

0.316

3

1.666

0.350

0.980 -

2.352

4

0.772

0.300

0.187 -

1.358

5

0.420

0.454

-0.480 -

1.300

6

0.116

0.166

-0.201 -

o. 4.40

7

-0.887

0.146

-1.160 - -0.332

8

0.294

0.125

0.049 -

0.540

9

0.605

0.457

-0.291 -

1.502

10

-0.233

0.203

-0.630 -

0.165

11

-0.020

0.202

-0.416 -

0.376

0.007

0.063

-0.116 -

0.131

95% Confidence Interval

~ighted by inverse of estirna.ted effect size variance.
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Figure 1.

Effect Size Estimates rn Parametric Analysis.

Study
11

10

9

a
7

J
2

-1.25 -1.0

-o.1s

-o.5 -0.25

o

0.25

o.:s

o.n

i.o

Effect Size

1.2:s

1.5

1.7:s

2.0

2.25

2.:s

65
gentamicin is associated with nephrotoxicity to a greater degree
than tobramycin).

The standard deviations of the estimated effect sizes ranged from
0.125 to 0.457.

The widest 95% confidence interval was 1.81 and the

narrowest was 0.26 (Figure 1).

'!he 95% confidence intervals included

zero for seven studies (suggesting no difference in the degree of
nephrotoxicity associated with gentamicin and tobramycin).

Of the four

studies in which the 95% confidence intervals did not include zero,
three enconpassed only positive values (suggesting gentamicin is
associated with nephrotoxicity to a greater degree than tobramycin) and
one encompassed only negative values (suggesting tobramycin is
associated with nephrotoxicity to a greater degree than tobramycin).
'!he estimated effect size for this series of 11 studies was
derived from the data shown in Table 7.

'!he estimated effect size for

this series was 0.007 with an associated standard deviation of 0.063
and

a 95% confidence interval of -0.116 to 0.131(Figure1).

Since the

aggregate effect sized estimate approxinates zero and the associated
confidence interval encompasses zero (Table 6), it would appear from
these results that there is no significant difference in the degree of
nephrotoxicity between gentamicin and tobramycin.

Technically, the

interpretation of these results is that after treatment with either
gentamicin or tobramycin, the sennn creatinine concentrations or
creatinine clearances would not be different.

Whether one chooses to

interpret this to mean the degree of nephrotoxicity does not differ
between the two drugs depends on whether

sen.mi

creatinine

concentrations and creatinine clearances are accepted as representative
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Table 7
Ccrrponents of Estimated Effect Size Calculation For

Para:rretric Study Series

Study
Numbe.r

1

0.131

0.056

2.345

17.692

0.306

2

-0.334

0.110

- 3.042

9.116

1.016

3

1.666

0.122

13.606

8.166

22.670

4

0.772

0.772

8.650

11.198

6.681

5

0.420

0.206

1.989

4.849

0.816

6

0.116

0.027

4.217

36.432

0.488

7

-0.887

0.021

-41.404

46.656

36.742

8

0.294

0.016

18.713

63.566

5.509

9

0.605

0.209

2.893

4.781

1. 751

10

-0.233

0.041

- 5.659

24.335

1.316

11

-0.020

0.041

- 0.495

24.489

0.010

1.813

251.551

77.306

Sum

~timated effect size. ~stimated effect size variance.
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of renal function.
HQ)llCXJeneity assumption.

'Ihe criterion for homogeneity among the

11 studies was not met [Q (10, N

= 11) = 77 .3,

12 < .05].

Inspection of

Table 6 and Figure 1 suggested. that Study 3 (Gocdwin, 1979) and Study 7
(Fong, Fenton,

&

Bird, 1981) may have contribute:i most to the

heterogeneity among the studies.

When these two studies were e:xclude:i

from the analysis, the rema.ining nine studies met the criteria for
homogeneity [Q (8, N

= 9) = 13.4,

12 > .05].

'Ihe range of the estimate:i effect sizes among the nine
homogeneous studies was from -0.334 to o. 772.

'Ihree of the estimate:i

effect sizes we.re negative and six we.re positive values.

'Ihe estimate:i

effect size standard deviations range:i from 0.125 to 0.457.

'Ihe

widest 95% confidence interval was 1.81 and the narrowest 0.49.

'Ihe

estimate:i effect size for the series of nine homogeneous studies was
0.15 with an asscx::iate:i standard deviation of 0.005 and a 95%
confidence interval of 0.01 to 0.29.
'Ihe interpretation of comparative nephrotoxicity changes when the
effect size estimate of only the nine homogeneous studies are
considere:i belaw.

Assl.Ilning a nonnal distribution, the average serum

creatinine concentration or creatinine clearance in patients treate:i
with gentamicin will exceed those of approximately 55% (standard nonnal
deviate of 0.15) of the patients treate:i with tobramycin.

Considering

the 95% confidence interval, the average serum creat.inine
concentration or creat.inine clearance in patients treate:i with
gentamicin could exceed those of as many as approximately 61% (standard
nonnal deviate of 0.29) or as few as 50% (standard deviate of 0.01) of
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the patients treated with tobramycin.

Again, the degree to which this

represents a difference in the camparative nephrotoxicity of gentamicin
arrl tobramycin will be depe:rxient on the degree to which these variables

are acc::epte:i as representative of renal function.

If these variables

are accepted as representative, the clinical significance of the
difference in camparative nephrotoxicity will be detennine:i by
counter-balancing the excess risk of nephrotoxicity with the economic
advantages associated with gentamicin use.
Sensitivity analyses.

Sensitivity analyses were conducted to

dete.nnine whether any relationships existed between estimated effect
sizes for irrl.ividual studies arrl certain study characteristics.

The

sensitivity analyses were restricted to the nine clinical trials that
were hOinOg"eneous.
With the

ex~ion

of one study, the sanple populations involve:i

mostly adult patients (Table 2) •

In

Study 4 (Itsarayoungyuen et al. ,

1982), the sample population include:i only neonates.
1. 5

days.

By

The mean age was

excluding this patient population, the estimate:i effect

size for the remaining series of eight studies was 0.113 with an
associated standard deviation of 0.073 arrl 95% confidence interval of

-o. 031 to o. 257. The assumption of hOinOg"eneity remaine:i after
exclusion of Study 4

(Q

(7, N

= 8) = 8.84

p > .05).

'Ihus, by

including only clinical trials involving adult patients, the estimated
effect size for the series of hOinOg"eneous studies involving mostly
adult patients does not change appreciably from when the study
involving neonates is included.
The basis for the effect size estimate in all but one of the
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studies was serum creat:i.nine concentrations.

In Study 8 (Schentag et

al. , 1981) , the basis for the effect size estimate was creatinine
clearance.

By excluding this study from the analysis, the estimated

effect size for the remaining eight studies was 0.082 with an
associated standard deviation of 0.087 and 95% confidence interval of
-o. 088

to O. 252.

Excluding Study 8 also reduced hetera;reneity among

the remaining eight studies [Q ( 7, N = 8) = 11. 4 9, p > . 05] •

'Ihus, by

excluding Study 8 so that only homogeneous clinical trials employing
serum creatinine concentrations as the endpoint are included in the
analysis, the change in the aggregate estimated effect size is not of
clinical significance.
As shown

in Table 2, for the studies reporting patient ages, the

mean ages were always very similar within each study; hovvever, the mean
ages differed between studies.

'Iherefore, mean age for both treatlnent

groups were pooled within each study and regressed on estimated effect
size.

Age ao:::ounted for about 32% of the variability in estimated

effect size; hovvever, this relationship did not reach statistical
significance

[x;-2 (6, N = 7) =

.318, p

= .085].

Of note was the

direction of the relationship (regression coefficient of -1.012).
age increased, estimated effect size decreased.

As

'Ihis ma.y have been due

to the inclusion of Study 4 (Itsarayoungyuen et al., 1982) which
included only neonates and was associated with a relatively high effect
size estimate.

When this study was taken out of the analysis, the

variability in estimated effect size associated with age decreased to
approximately 9%; however, this relationship also did not reach
statistical significance cr-2 (5,

N = 6) = o.089,

p

= .264).

'Iherefore,
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it does not appear that any differences in nephrotoxicity associated.
with gentamicin and tobramycin are linearly related. to pa.tient age
(Table 8).
In the studies reporting the duration of gentamicin and

tobramycin use, the durations of use were similar for both treatment
groups for nearly all of the studies (Table 2) .

Therefore, the

durations of gentamicin and tobramycin use were pooled within studies
and regressed on effect size estimates to determine 'Whether duration of

use affected effect size estimates (Table 8) •

OJ.ration of

aminog1ycoside use accounted. for approximately 21% of the variability
in estimated. effect size; h01Never, this relationship did not reach
statistical significance [i;2 (7, N

= 8) =

.209, 12

=

.121].

Thus, it

does not appear that any differences in nephrotoxicity associated with
gentamicin and tobramycin are linearly related. to the duration of use.
Differences in initial renal function between treatment groups,
as :measured by initial serum creatinine concentrations or creatinine
clearances, existed. arocmg some of the clinical trials (Table 2);
h01Never, not all were clinically significant.

The differences between

initial serum creatinine concentrations or creatinine clearances
between treatment groups were regressed on effect size estimates (Table
8).

The differences in initial serum creatinine concentrations and

creatinine clearances accounted. for approximately 16% of the
variability in estimated. effect size; however, this relationship did
not reach statistical significance ri;2 (7,

N = 8) =

.156, 12 = .159].

Variation existed. ainOng- the studies in the differences between
the treatment groups in the incremental chang-es during therapy in serum
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Table 8
Sensitivity Analysis - Linear Regre.ssian Analyses

Variable

C.oef ficient

Ad.justed R2

D.F.

a

Age(l)c

-1.012

.318

6

.09

Age(2)d

-0.045

.089

5

.26

Duratione

-0.061

.209

7

.12

Initial CRf

0.007

.156

7

.16

-0.002

7

.88

7

• 71

7

.07

Randanh

0.105

.ooo
.ooo

Blindi

0.457

.299

Increase CRg

'il.F. =degrees of free:'ian. hp =two-tailed probability of
CXJefficient not ~ zero. cAge(l) =pooled ages for all
harogeneous studies. ""Age(2) =pooled ages for all hqrogeneous
studies excluding the study with neonates (Study 9)
~led
duration of gentamicin and tobramycin use (days). foifference
in initial serum creatinine concentration or creat.i.n.ine
clearance between gentamicin arrl tobramycin groups. gDifference
in incrE!l'elltal increase in serum creatinine concentration or
~reatinine clearance between gentamicin arrl tobramycin gp:>UpS •
..Whether patients were ra.n:lanized to treatment groups. ~ether
study was blinded.
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creatinine concentrations or creatinine clearances (Tables 2 and 5).
'lbe difference in incremental change between thetreatment groups were
re;Jressed on the effect size estllna.tes (Table 8).

'lbe incremental

change in serum creatinine concentration or creatinine clearance did
not account for any variability in the estima.ted effect size

c.r2

=.000):

therefore, it does not appear that any differences in the

incremental changes in measurements of renal function between
gentarnicin and tobramycin are associated with a difference in
nephrotoxicity.
Only three studies were blinded (Study 9 (Feig et al., 1982),
Study 6 (Smith et al., 1980), and Study 4 (Itsarayoungyuen et al.,
1982)] (Table 6).

Blinding status did not appreciably affect effect

size estima.tes and did not reach statistical significance

[.r2

(7,

N = 8) = .105, p = .71].

'1bree

studies did not randomize patients to either treatment

group (Study 2 (Kahlmeter et al., 1978), Study 5 (IX>nta & I.embke,
1985), and Study 8 (Schentag et al., 1981)] (Table 8).

Randomization

status accounted for approxima.tely 30% of the variability in effect
size estima.tes; however, this relationship did not reach statistical
significance [_r2 (7, N = 9) = .299, p

= .07). Of note was the

direction of the relationship (regression coefficient of 0.105)
suggest:i.rq that higher effect size estllna.tes (i.e. , differences in the
degree of nephrotoxicity between gentarnicin and tobramycin) may be
expected more often in randomized studies.

Nonparametric Analyses
Effect size estllna.tion.

'Ihe nonparametric estllna.tions of effect
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size were based on the differences in the proportions of studies in
which the nephrotoxicity incidence between the gentamicin groups and
tobramycin groups reached statistical significance.

'Ihe proportion of

studies in which the difference in the incidence of nephrotoxicity
between gentamicin and tobramycin reached statistical significance by

the Relative Deviate Test was 0.231 (3/13) with an associated 95%
confidence interval of 0.002 to 0.437.

'Ihe estimated effect size based

on this proportion was 0.117 with an associated 95% confidence interval
of

o to 0.226 (Table 9).
Sensitivity Analysis.

used

When the seven studies that could only be

in the nonparametric analyses were considered (Studies 12-18) , the

proportion in which the difference in nephrotoxicity incidence between
gentamicin and tobramycin reached statistical significance was

O.14

(1/7) with an associated 95% confidence interval of -0.116 to 0.402.
The estimated effect size based on this proportion was 0.080 with an
associated 95% confidence interval of -0.60 to 0.200.
In the nonparametric analysis that included the studies that were
also in the parametric analysis, one of the studies included [Study 7
(Fong et al., 1981) J was one that was excluded in the homogeneous
parametric analysis.

When this study was eliminated from the

nonparametric analysis, the proportion of studies in which the
difference in nephrotoxicity incidence between gentamicin and
tobramycin reached statistical significance was 0.25 (3/12) with an
associated 95% confidence interval of 0.005 to 0.495.

'Ihe estimated

effect size was 0.134 with an associated 95% confidence interval of o
to 0.232.

Table 9
Estimated Effect Sizes for lbnpara:rootric Analyses

Proportion of
Dif f.

Signi~

95% Confidence
Interval of
Proportion

Estimated
Effect. Size

1

3/13 (23%)

-0.008 - 0.437

0.117

0.000 - 0.226

2

3/12 (25%)

-0.001 - 0.469

0.134

o.ooo -

3

1/7

-0.116 - 0.402

0.080

Study
Groupa

(14%)

95% Confidence
Interval of
Effect Size

0.232

-0.060 - 0.200

Clgtuiy groupin;Js:
1 =All stu:iies used in nonpara:rootric analysis (Studies 6-18).
2 =Studies used in nonpara:rootric and harogeneous para:rootric analyses (Stu:iies 6, 8-18).
3 = Stu:iies only used in nonpara:rootric analysis (Stu:iies·12-l8).

~ of stuiies in which differences
m.:mDer of studies.

in proi;x>rtions nei;hrotaxic significant/total
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'lhe nonparametric estimations of effect size were remarkably
similar to those resulting from the parametric analysis.

If one

accepts the arbitrary definitions of nephrotoxicity in the studies used
in the nonparametric analyses and serum creatinine concentrations or
creatinine clearance as markersof nephrotoxicity, the interpretations
of the nonparametric analysis results would parallel those of the
parametric analysis.

Using the same assunptions, it could be suggested.

that the modified vote-counting method of Hedges and Cl.kin (1985) may
be a reliable alteniative 'When the empirical research substrate
provides only limited. infonnation (Table 10 and Figure 2).
Summary

Eighteen clinical studies related. to the corrparative
nephrotoxicity of gentamicin and tobramycin met the criteria for this
meta-analysis.

Analysis by two different methods indicated. that if

there is a difference in nephrotoxicity between the two drugs, it is
not of a great magnitude.

In

addition, none of the selected. covariates

affected. the difference in nephrotoxicity between gentamicin and
tobramycin to an extent that reached statistical significance.
Secondarily, the m::rlified vote-counting method produced very
similar results as the parametric analysis (Table 10 and Figure 2).
Thus, despite that conventional vote-counting methods are often
dismissed as not being useful, the modified vote-counting method of
Hedges and cl.kin (1985, chap. 4) may indeed have a role in situations
'Where the ernpirical research under investigation does not provide
enough infonna.tion to apply the more parametric procedures.
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Table 10

Surrmary of Estimated Effect Sizes

Study Grrupa

Mean Est:.ilrated

Effect Size

95% Confidence
Interval

Parametric Analyses
1

0.007

-0.116 - 0.131

2

0.150

0.010 - 0.290

3

0.113

-0.031 - 0.257

4

0.082

-0.088 - 0.252

Nonpararretric Analyses
5

0.117

o.ooo -

6

0.134

0.000 - 0.232

7

0.080

-0.060 - 0.200

0.226

~ttrly groupin3'5:
1 =All stu::lies in parametric analysis (Stu::lies 1-11).
2 = Harogeneous studies in parametric analysis (Study
grouping 1 minus Study 3 and Study 7).
3 =Study grouping 2 minus Study 4 (neonates).
4 = Stt.rly grouping 2 minus Study 8 (creatinine clearance).
5 =All studies in nonparametric analysis (Studies 6-18).
6 = Stu:lies in nonpararretric an::l harogeneous pararretric
analyses (Studies 6, 8-18).
7 = Stu:iies only in nanpa.rarretric analysis (Studies 12-18).
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Figure 2.

Effect Size Estimates and 953 Confidence Jntervals
For Parametric and Nonparametric Analyses.

Study

Group*
7
Nonparmetric
Analyses

6

5

4
Parametric
Analyses

3

2

-0.2 -0. 1

0

0. 1

Effect Size

* As

listed in Table l 0.

0.2

0.3

SUMMARY

Aminoglycoside antibiotics are brp::>rtant agents in the
treatment of serious to life-threatening bacterial infections.
However, the use of these antibiotics is hanpere:l by an association
with nephrotoxicity.

Research

efforts have been undertaken to

determine whether any of the aminoglycoside antibiotics is less
nephrotoxic than the others.

Corrparisons of two aminoglycoside

antibiotics in particular, gentamicin and tobramycin, have prcx:luced.
equivocal results.

Some data have suggeste:l that gentamicin is

associate:l with nephrotoxicity to a greater degree than tobramycin
while other data have suggeste:l no difference.

Publishe:l reviews of

the empirical gentamicin and tobramycin comparisons have been as
equivocal with re;Jard to their ccnuparative nephrotoxicity as the
empirical research they covere:l.

Hc:Mever, none of the publishe:l

reviews applie:l systematic meta-analytical techniques.
In

the investigation rep::>rted here, meta-analytical techniques

were use:l to assess the empirical research conparing the nephrotoxicity
of gentamicin and tobramycin in humans.

Specifically, effect sizes

were est.imate:l using the parametric approach of standa:rdize:l mean
differences.

In addition, a mcx:lifie:l vote-counting prcx::e::lure was use:l

in those situations where there was insufficient info:nnation for
parametric analysis.

When all studies in the parametric analysis were

include:l, there appeared. to be no difference in the degree of
nephrotoxicity between gentamicin and tobramycin; hc:Mever, when only
78
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homogeneous studies were included, it appeared that gentarnicin may
Weed be associated with nephrotoxicity to a slightly greater degree.
Interestingly, effect size estimates derived using the m::xlified
vote-counting method produced similar results

and.

inte:rpretations.
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